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Abstract 
Liver disease causes an estimated 36,000 deaths in the United States each year. Currently, 
to detect liver disease, an invasive biopsy is required. Other, less invasive diagnostic 
alternatives are needed. The purpose of this study was to assess the efficacy of a modified 
form of sonographic screening, including portal, hepatic, and splenic venous pressure, 
hepatic venous waveform analysis, portal vein diameter, and echogenicity of liver 
parenchyma in predicting liver disease. The study was based on conversion of a velocity 
measurement to a pressure gradient, allowing a fluid comparison between known 
catheterization venous pressures and sonographic Doppler-derived pressure gradients. 
This study was a secondary data analysis of a data set from 546 patients who received 
abdominal sonograms at a medical facility in the western United States between March 
2010 and December 2010. The dependent variable was liver disease and the independent 
variables were ECHOGRADE, hepatic venous waveform (HVW), splenic vein pressure 
gradient (SVPG), modified portal vein pressure gradient (MPVPG), and hepatic vein 
pressure gradient (HVPG). Logistic regression was used to analyze the data. 
ECHOGRADE, HVW, and MPVPG in males were found to be statistically significant in 
detecting liver disease, supporting the theoretical framework and thus documenting a 
novel use of Doppler for the detection of liver disease. The social change significance of 
these results is to provide clinicians with an alternative, noninvasive method of 
diagnosing early liver disease before it progresses into chronic liver disease. With earlier 
detection, severe adverse health outcomes leading to irreversible liver cirrhosis may be 
avoided.   
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Chapter 1: Introduction to the Study 
Background 
 Chronic liver disease and liver cirrhosis are major public health problems 
worldwide. In 2004, these conditions were associated with nearly 40,000 deaths and a 
cost of at least $1.4 billion for medical services in the United States alone (Centers for 
Disease Control and Prevention [CDC], 2009). Chronic liver disease caused by hepatitis, 
alcoholism, or nonalcoholic fatty liver disease (NAFLD) is a major health problem that 
results in increased morbidity and greater expenditures of health dollars (CDC, 2005). 
The condition has been associated with 20% to 30% of all cases of cirrhosis (CDC, 
2009). Early detection of liver fibrosis, which is the precursor for liver cirrhosis, is 
important to the selection of treatment strategies, as well as to predicting overall 
prognosis. The gold standard for assessing liver fibrosis is a liver biopsy; however, this 
procedure is invasive and carries risks (Goodman, 2007). Complications of liver biopsy 
may include bleeding, pneumothorax, and possible perforation of other organs such as the 
colon or gallbladder (Herrine & Friedman, 2005). Due to their invasive nature, liver 
biopsies are both costly and time-consuming. According to the CDC (2008), about 
70,000 cases of liver biopsy result in complications each year, but this number likely 
represents only a fraction of cases occurring. The estimated cost per biopsy ranges 
between $2,000 and $7,000, depending on the biopsy method, use of ultrasound 
guidance, and complication (Rockey, Caldwell, Goodman, Nelson, & Smith, 2009). 
Despite the limitations of liver biopsy, the procedure remains the gold standard, for lack 
of better alternatives to assess the severity of liver fibrosis (Bonekamp, Kamel, Solga, & 
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Clark, 2009). Alternative noninvasive tests might predict the chronic progression of liver 
disease so clinicians need not rely on liver biopsy alone.  
 The ideal noninvasive marker should accurately detect the presence or absence of 
significant disease. High sensitivity, specificity, and accuracy would be required of the 
marker. It must also be readily accessible, available, and reproducible, with low 
interlaboratory or intraobserver variability, and must demonstrate applicability to liver 
disease of various etiologies (Bonekamp et al., 2009). Current noninvasive methods of 
measuring liver fibrosis include serum markers (Castéra, Forns, & Alberti, 2008) and 
transient elastography (TE), also known as Echosens FibroScan® (Bonekamp et al., 
2009). Serum markers increase with acute liver disease and cannot always distinguish 
between acute and chronic disease (Obrador et al., 2006). Elastography has decreased 
sensitivity in obese patients (Castéra et al., 2008). The objective of this study was to 
develop a noninvasive sonographic screening method that included portal, hepatic, and 
splenic venous pressure; portal vein diameter; and the echogenecity of liver parenchyma 
for use in predicting the existence of chronic liver disease, even for patients who are 
moderately obese (body mass index [BMI] < 35). The development of a noninvasive 
method holds potential for social change because detecting the presence of liver fibrosis 
before the patient becomes chronically ill allows for earlier treatment options (Castéra et 
al., 2008). 
 Understanding the disease burden of viral hepatitis requires awareness of the 
chronic sequelae of hepatitis infection, which can range from asymptomatic chronic 
infection to chronic hepatitis (Heymann, 2004), cirrhosis (Nelson & Williams, 2007), and 
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primary liver cancer (Galfione, Kronforst, & Conlon, 2007). A healthy liver serves 
several functions including the synthesis of proteins; the processing of amino acids, 
carbohydrates, lipids, and vitamins; the detoxification of pollutants; and the secretion of 
endogenous waste products into bile (Galfione et al., 2007). In essence, the liver acts as a 
filter, with architecture similar to a sponge when of normal status. When the liver tissue 
becomes fibrotic, these processes malfunction, leading to liver failure (Nicolau, Bianchi, 
& Vilana, 2002). The texture of a fibrotic liver is nodular.  
 Fibrosis is associated with difficulty in the portal vein, preventing the liver from 
functioning normally. In response to these circulatory difficulties, the portal vein dilates 
to deliver increased blood flow to the damaged liver. With advanced liver fibrosis 
(cirrhosis), blood flow can reverse because it is easier for the blood to find another path 
to the inferior vena cava rather than course through the cirrhotic liver. This condition is 
portal hypertension (Hagen-Ansert, 2006). Cirrhosis can cause liver failure, portal 
hypertension, esophageal varices, ascites, and hepatic encephalopathy (Heymann, 2004). 
Liver changes can manifest with sustained hepatitis C (HepC) infection, including fatty 
infiltration, a condition in which the individual hepatocytes fill with fat and subsequently 
become fibrotic with cirrhosis (Bonekamp et al., 2009).  
Etiology and Epidemiology of Hepatitis 
Acute Hepatitis 
 Hepatitis refers to an inflammation of the liver (Heymann, 2004). Causal factors 
include infectious agents (Angulo, 2002), drugs (W. M. Lee, 2003), or toxins/toxicants 
(W. M. Lee, 2003). The function of the liver in healthy individuals is to produce clotting 
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factors, cholesterol, plasma proteins, and glycogen (Heymann, 2004). Additionally, the 
liver detoxifies drugs and stores fat-soluble vitamins (W. M. Lee, 2003). Hepatitis 
compromises the ability of the liver to perform these functions and damages liver cells. 
Individual hepatocytes in the liver, once inflamed, can become swollen and unable to 
function (W. M. Lee, 2003). Illnesses associated with liver inflammation range from mild 
to life threatening and can be acute or chronic (Hagen-Ansert, 2006).  
 Symptoms of acute hepatitis typically include acute jaundice, dark urine, 
anorexia, malaise, extreme fatigue, and right upper quadrant tenderness (Galfione et al., 
2007). HepC is a precursor for hepatocellular carcinoma (HCC; Hagen-Ansert, 2006). 
Many viruses have been associated with hepatitis, including the hepatitis A, B, C, D, and 
E viruses (CDC, 2009). The following sections describe the epidemiology and etiology of 
hepatitis.  
Hepatitis C Virus 
 The hepatitis C virus (HCV) that causes HepC is a spherical, enveloped, 
ribonucleic acid member of the Flaviviridae family and is approximately 50nm in 
diameter (Heymann, 2004). HCV is associated with a moderate to high mortality rate as 
well as a high risk of chronic illness (Heymann, 2004). Measuring the burden of HCV 
requires information on hospital utilization and mortality related to chronic hepatitis, 
cirrhosis, and liver cancer, as well as data from cancer registries (National Cancer 
Institute [NCI], 2010). According to the National Foundation for Infectious Disease (as 
cited in NCI, 2010), HCV is responsible for approximately 8,000 to 10,000 deaths each 
year and accounts for almost half of the nearly 4,000 liver transplantations performed 
5 
 
 
annually. The viral ribonucleic acid is in blood, saliva, seminal fluid, tears, ascitic fluid, 
or cerebral spinal fluid (Nelson & Williams, 2007). The most common routes of 
transmission are injection, drug use, donated blood, blood products, transplanted organs, 
needle-stick injuries (for those who work in the health care setting), and birth to a HCV-
infected mother (CDC, 2009).  
 Symptoms of HCV infection are indistinguishable from other types of hepatitis 
(Tilg & Diehl, 2000). Acute HCV infection typically goes unnoticed and can persist for 
several years either without symptoms or with vague symptoms such as malaise (Tilg & 
Diehl, 2000). Over time, approximately 2% to 25% of all individuals with HCV will 
develop liver cirrhosis and/or liver cancer (Heymann, 2004). HCV-infected individuals 
may be asymptomatic for several years, in some cases more than 20 years, making 
estimates of infected individuals difficult (Obrador et al., 2006). Although there were 
only 802 reported cases of HCV infections in the United States in 2006, a much higher 
number—approximately 19,000 new cases—is estimated after adjusting for those who 
are asymptomatic (CDC, 2008). As of early 2011, chronic HCV infection affected 
approximately 3.2 million individuals in the United States (CDC, 2011).  
 HCV infection reached its peak in the early 1990s, so the infection is currently 
most prevalent in those born between 1945 and 1965 (CDC, 2011). Although the number 
of cases of HCV infection has declined in the United States since that peak period, 
possibly due to increased awareness of the risk factors associated with blood transfusions 
and drug use (Sy & Jamal, 2006), HCV infection continues to be a major burden of 
disease throughout the world (Obrador et al., 2006). The CDC has suggested that the 
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incidence of HepC in the United States has decreased since 1988, but the latency period 
of HepC, that interval between contraction of the disease and the appearance of 
symptoms, is lengthy. The World Health Organization (2008) estimated approximately 
3% of the worldwide population—over 170 million people—had HCV in 1999.  
 Hepatocellular carcinoma (HCC) is a primary malignant liver tumor; it is the most 
common and severe complication of HepC and cirrhosis (Nicolau et al., 2002). 
According to the NCI (2010), HCC is the fourth most common cancer in the world. 
Annual age-adjusted incidence rates vary from 2.1 per 100,000 in North America to 80 
per 100,000 populations in China (NCI, 2010). Across all racial/ethnic groups, men 
contract HCC more often than do women; the disease is most prominent among Chinese 
Americans, in whom the annualized incidence rate of HCC among men is 20.9 per 
100,000 and, among women, 8.0 per 100,000 (NCI, 2010). 
Alcoholic Liver Disease 
 The most common toxicant associated with hepatitis is alcohol (Galfione et al., 
2007). Alcoholic liver disease, also referred to as alcoholic hepatitis or steatohepatitis, is 
considered the third leading preventable cause of death in the United States (Lucey, 
Mathurin, & Morgan, 2009). Mortality typically ensues after decades of alcohol abuse, a 
mean daily intake of approximately 100 g (i.e., approximately 3.6 oz) of alcohol (Lucey 
et al., 2009). Signs and symptoms of alcoholic hepatitis include rapid onset of jaundice, 
fever, enlarged and tender liver, ascites, and possible encephalopathy (Heymann, 2004). 
Alcoholic hepatitis begins with fatty accumulation within the individual hepatocytes 
(Angulo, 2002). In its early stages, alcoholic hepatitis is reversible. With progressive 
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alcoholic abuse, the liver enlarges and, with that change in size, its architecture becomes 
disrupted and fibrotic (W. M. Lee, 2003).  
 Once the liver has become fibrotic and nodular, cirrhosis occurs. Alcoholic 
cirrhosis is an advanced liver disease characterized by diffuse and extensive liver fibrosis 
and loss of liver function (Nelson & Williams, 2007). Laboratory findings resulting in a 
diagnosis of cirrhosis include a decreased platelet count, an increased international 
normalized ratio, and an increased ratio of alanine aminotransferase (ALT) to aspartate 
aminotransferase (AST); that is, > 2 (Burroughs & Cholongitas, 2007). AST and ALT 
leak from damaged cells and are indicators of liver injury (Angulo, 2002). Elevated white 
blood count, neutrophil count, and total serum bilirubin levels are additional indicators of 
liver damage (Lucey et al., 2009). Although these various laboratory test results are 
irrefutable, microscopic analysis of a small piece of the liver will determine a definitive 
diagnosis of alcoholic hepatitis. Microscopic analysis of an alcoholic liver reveals 
ballooned and swollen individual hepatocytes that often contain eosinophilic inclusion 
bodies known as Mallory bodies or alcoholic hyaline (Lucey et al., 2009). The presence 
of large fat globules (i.e., steatosis) is common in alcoholic hepatitis. Over time, the fat 
globules can turn into liver fibrosis (W. M. Lee, 2003).   
An individual with alcoholic hepatitis metabolizes alcohol through an oxidative 
process from acetaldehyde to acetate (W. M. Lee, 2003). The process promotes 
lipogenesis, which in turn leads to fat-filled hepatocytes and subsequent remodeling of 
the liver (Lucey et al., 2009). The increased fat content within the individual hepatocytes 
reduces the ability of the liver to complete vital processes such as metabolism and 
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filtration (Tilg & Diehl, 2000). Sonography is helpful in identifying hepatic abscesses, 
HCC, and accompanying ascites (Nicolau et al., 2002). Sonography-guided paracentesis 
(i.e., aspiration of ascites) is also routinely performed (Hagen-Ansert, 2006) to confirm 
the extent of liver damage. As with other acute liver diseases, alcoholic hepatitis may 
lead to chronic liver failure, fibrosis, cirrhosis, and possibly HCC (Obrador et al., 2006). 
Alcoholic cirrhosis may lead to life-threatening biliary obstruction, portal hypertension, 
ascites, and esophageal varices with possible upper gastrointestinal bleeding (Lucey et 
al., 2009).  
Complications of advanced cirrhosis include hepatic encephalopathy (i.e., 
inflammation of the brain; Nelson & Williams, 2007) and a significant risk of HCC (NCI, 
2010). Portal hypertension occurs when nodularity within the cirrhotic liver causes 
increased intrahepatic pressure (Sharara & Rockey, 2001). Because blood follows the 
path of least resistance, portal venous flow can reverse and find another pathway back to 
the inferior vena cava (Hagen-Ansert, 2006). Portal hypertension can lead to the 
formation of gastric or gastroesophageal varices, which have a high risk of rupture 
(Castéra et al., 2008). The morbidity and mortality of an individual increases with the 
presence of esophageal varicies. Endoscopy has been used to determine the size and 
progression of esophageal varices, along with catheterization techniques used to measure 
the hepatic venous pressure gradient (HVPG) employed to determine which patients are 
at greatest risk for rupture (HVPG > 12mmHg; Sharara & Rockey, 2001).    
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Nonalcoholic Liver Disease 
Alcohol abuse is not the only risk factor for liver disease. NAFLD is a catchall 
term for a condition also known as nonalcoholic steatohepatitis, diabetic hepatitis, fatty-
liver hepatitis, and nonalcoholic Laennec’s disease (Angulo, 2002). NAFLD is the 
preferred term because it encompasses a wide range of conditions including mild 
steatosis advancing to steatohepatitis, liver fibrosis, and finally cirrhosis (Ratziu et al., 
2006). The clinical presentation of an individual with NAFLD is similar to that of 
alcoholic liver disease; however, the pathogenesis is distinctly different (Tilg & Diehl, 
2000).  
 NAFLD is the most common liver disease in the United States (Angulo, 2002). 
An estimated 70 million adults in the United States have liver disease (Bellentani & 
Marino, 2009). Multiple risk factors contribute to NAFLD, and the disease affects 10% to 
24% of the populations in various countries (Angulo, 2002). Risk factors for NAFLD 
include obesity (Fan & Farrell, 2008), Type 2 diabetes mellitus (Angulo, 2002), and 
hyperlipidemia (Fan & Farrell, 2008). Regardless of the degree of obesity, the presence 
of diabetes mellitus significantly increases the risk and severity of associated NAFLD (J. 
Y. Lee et al., 2007). People with truncal obesity are at higher risk for NAFLD, even with 
a normal BMI (Angulo, 2002).  
 The steadily increasing trend of obesity in the United States (CDC, 2011) and the 
association between obesity and Type 2 diabetes explains the concurrent increase in the 
incidence and prevalence of NALFD. Clinical indicators of NAFLD include 
hepatomegaly, decreased platelet count, and mild to moderately increased serum levels of 
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AST, ALT, or both (Ratziu et al., 2006). As the degree of fibrosis increases, the AST: 
ALT ratio increases (Obrador et al., 2006). Other laboratory abnormalities indicative of 
NAFLD include hypoalbuminemia, a prolonged prothrombin time, and 
hyperbilirubinemia as the liver disease progresses (Angulo, 2002). Ultrasound findings 
with NAFLD include increased echogenicity compared to that found in the kidneys, and 
ranges from mild coarseness to a loss of visualization of the vessels and diaphragm 
(Hagen-Ansert, 2006).  
 Sonography has historically been useful in attempting to detect fatty infiltration 
leading to fibrosis or cirrhosis (Nicolau et al., 2002), but the increase in obesity has 
caused difficulty in distinguishing between fatty infiltration and fibrosis by imaging 
alone. Supplementation of sonographic images with Doppler-derived pressure gradients 
has been posited to increase sensitivity of detection of chronic liver disease (Obrador et 
al., 2006). A diagnosis of NAFLD includes a combination of unexplained hepatomegaly, 
elevated AST and ALT, and findings of sonographic or computed tomography suggestive 
of fatty infiltration of the liver. After NAFLD has been diagnosed, liver biopsy 
determines the severity of liver disease (Herrine & Friedman, 2005).  
Research Gaps 
The literature reviewed for this study revealed the current state of knowledge was 
insufficient to support the value of any alternative measures to liver biopsies as a means 
of predicting when acute hepatitis or acute liver disease will turn to liver fibrosis, leading 
to irreversible cirrhosis. A combination of biomarkers and TE provide assistance in 
detecting liver fibrosis (Castéra et al., 2008), but these methods have not yet replaced 
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liver biopsy. The driving force behind this study was to determine the level at which the 
liver is no longer porous, and to enable a better understanding of when fibrosis is causing 
an increase in venous pressure. Endoscopic pressure gradients can accurately detect 
HVPGs when liver disease is chronic and extensive (Sharara & Rockey, 2001). The 
measured pressure gradient used in endoscopy is mmHg. An alternative method of 
predicting liver fibrosis as a pressure gradient would provide a comparative analysis and 
possibly aid in earlier detection of chronic liver changes such as fibrosis/cirrhosis.  
A meta-analysis conducted by Bonekamp et al. (2009) demonstrated that hepatic 
fibrosis, unlike cirrhosis, may be reversible. Consequently, the ability to detect early liver 
fibrosis was of immense clinical utility and potential social benefit. The analysis of 153 
studies related to alternative approaches to the prediction of chronic liver disease found 
elastography (either ultrasound or magnetic resonance imaging [MRI]) to be the most 
promising (Bonekamp et al., 2009). Other proposed methods included a combination of 
biomarkers, elastography, and ultrasound techniques. Alternative noninvasive tests will 
predict chronic liver disease so that clinicians will not rely on liver biopsy alone and the 
patient can receive beneficial treatment before early liver disease manifests irreversible 
damage.  
The liver is a porous organ that allows for fluid exchange of cellular contents and 
acts as a highly effective filter. The study assumed that, in the setting of fatty infiltration, 
the liver remains porous and the vascular network is undisturbed. When the liver 
becomes fibrotic or cirrhotic, the ability of the vessels to supply blood to and from the 
liver is disturbed due to the nodular texture of the liver. A review of the literature, 
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discussed in detail in chapter 2, yielded no prior study having assessed Doppler-derived 
portal, splenic, and HVPGs hepatic venous pressure gradients (mmHg) in conjunction 
with sonographic assessment of portal vein diameter and liver echogenicity grading 
across the spectrum of liver disease. The lack of knowledge about the association 
between chronic liver disease and intraabdominal venous pressures necessitated further 
investigation. The rationale for why these variables would predict liver fibrosis/disease 
was based on the laws of fluid hemodynamics. As the radius of a vessel decreases, the 
velocity and/or pressure increases. As the liver becomes more nodular, it was 
hypothesized that the lumen of the veins becomes more narrow, causing a reduction in 
size and increase in the venous pressure.  
High-priority research areas included a method to quantify the Doppler-derived 
portal vein and splenic vein pressure gradient, the hepatic venous waveform analysis, 
liver echogenicity, and portal vein diameter. The Doppler-derived pressure gradient 
model in this study was a quantitative tool designed to determine the presence or absence 
of chronic liver disease. Stauber and Lackner (2007) recommended defining a diagnostic 
algorithm for staging hepatic fibrosis. The identified challenge was to develop and 
validate methods that can be routinely applied and provide clinically meaningful results 
that add substantially to routine clinical assessment, and potentially reduce the need for 
liver biopsy, at least in some patients. Validation of such a method was a high-priority 
research need. 
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Problem Statement 
Chronic liver and gallbladder disease, chronic hepC, and liver cancer collectively 
account for approximately one quarter of direct health care costs, amounting to $9.1 
billion (Kim, Brown, Terrault, & El-Serag, 2002). The problem is high echogenicity of 
the liver used to be a highly reliable predictor of liver fibrosis (Hagen-Ansert, 2006); 
however, the increased prevalence of patient obesity has made echogenicity a less 
reliable indicator (Fan & Farrell, 2008). It is possible to have increased echogenicity 
secondary to fatty infiltration of the liver due to obesity and not due to liver fibrosis 
(Hagen-Ansert, 2006). It would prevent needless biopsies and permit early treatment of 
liver disease if Doppler studies could determine whether the liver has fatty infiltration of 
the liver due to obesity, or is actually fibrotic due to chronic liver disease (Zwiebel & 
Pellerito, 2005). The identified problem was that sonographic imaging alone is no longer 
as effective in detecting liver disease due to the increase in obesity. Additionally, 
noninvasive tests reduce the amount of complications related to liver biopsies. This study 
described the relationship between the portal vein diameter, portal, hepatic, and splenic 
pressure gradient, the hepatic venous waveform, and the echograde; and the prediction of 
liver disease.    
Nature of the Study 
Multiple logistic regression models assessed the effect of baseline characteristics 
on the presence of chronic liver disease. Many studies have proposed noninvasive tests to 
replace liver biopsy (Barbaro et al., 2000; Liu et al., 2007; Obrador et al., 2006; 
Sebastiani, 2009). These studies examined either a single biochemical marker or a 
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combination of biochemical markers and other noninvasive imaging. A primary goal of 
this study was to identify the relationship between portal, hepatic, and splenic venous 
pressure; portal vein diameter; and the echogenicity of liver parenchyma and liver 
disease. A secondary goal of the study was to develop a sonographic screening method 
that would predict chronic liver disease using Doppler-derived pressure gradients rather 
than rely on current velocity measurements alone. Increases in portal vein diameter in 
patients with chronic liver disease was calculated and then applied to a mathematical 
modifier. This calculation resulted in a modified pressure gradient that correlated with 
invasive pressure gradients obtained in the endoscopy laboratory. The dependent variable 
in the study was the presence or absence of chronic liver disease. The independent 
variables were liver echogenicity, portal vein diameter; splenic, hepatic, portal, modified 
portal venous pressure gradient; and hepatic venous waveform analysis.  
Research Question 
 The following research question guided the study: Will the hepatic venous 
pressure gradient (HVPG), the hepatic venous waveform (HVW), the portal vein 
diameter (PVD), the portal vein pressure gradient (PVPG), the modified portal vein 
pressure gradient (MPVPG), the splenic vein pressure gradient (SVPG), or the echograde 
(ECHOGRADE) predict the presence or absence of liver disease after controlling for age, 
ethnicity, and BMI, and after stratification by gender?  
 The following were the null and alternative hypotheses: 
 Null hypothesis: The hepatic venous pressure gradient (HVPG), the hepatic 
venous waveform (HVW), the portal vein diameter (PVD), the portal vein 
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pressure gradient (PVPG), the modified portal vein pressure gradient 
(MPVPG), the splenic vein pressure gradient (SVPG), or the echograde 
(ECHOGRADE) will not predict the presence or absence of liver disease after 
controlling for age, ethnicity, and BMI, and after stratification by gender.  
 Alternate hypothesis: One or more of the following, including hepatic venous 
pressure gradient (HVPG), the hepatic venous waveform (HVW), the portal 
vein diameter (PVD), the portal vein pressure gradient (PVPG), the modified 
portal vein pressure gradient (MPVPG), the splenic vein pressure gradient 
(SVPG) or the echograde (ECHOGRADE) will predict the presence or 
absence of liver disease after controlling for age, ethnicity, and BMI, and after 
stratification by gender.  
Purpose of the Study 
The purpose of the study was to address the gap in related research by linking 
Doppler-derived pressure gradients with liver fibrosis. This research was the first 
independent study to assess the value of Doppler-derived portal, splenic, and hepatic 
venous pressure gradients in conjunction with sonographic assessment of hepatic venous 
waveform, portal vein diameter, and liver echogenicity for the diagnosis of liver disease. 
The study provided an important step in the development of a new noninvasive method 
that should be of great benefit to patients. I used multiple logistic regression and receiver 
operating characteristics (ROC) curves to test the hypotheses. The study set the stage for 
future research to evaluate the effectiveness of the Doppler-derived pressure gradients in 
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determining associations between acute liver diseases before life-threatening, chronic 
liver changes manifest. 
Theoretical Foundation 
The mechanism of action in liver fibrosis provided the theoretical foundation for 
this study. Liver fibrosis is the excessive accumulation of extracellular matrix proteins, 
including collagen, which manifests with most liver disease (Rosenberg, 2003). 
Advanced liver fibrosis leads to cirrhosis, liver failure, and portal hypertension that often 
requires liver transplantation (Rosenberg, 2003). These conditions often occur after initial 
inflammation of the liver (Herrine & Friedman, 2005), referred to as hepatitis. Doppler is 
the mechanism used to test intraabdominal venous pressure with the use of an ultrasound 
machine (Dietrich et al., 1998). The ultrasound transducer produces transmitted sound 
waves in the body. An image is produced on the screen of the ultrasound machine by the 
reflection of echo signals bouncing off various tissues in the body. The source of the 
reflected echo signal is moving red blood cells. A Doppler shift determines the difference 
in frequency between the transmitted frequency and reflected frequency.  
The reflected signal indicates both direction and velocity of the red blood cells 
traveling within the region of interest. On the image display, the y-axis represents the 
velocity and the x-axis represents time (Zwiebel & Pellerito, 2005). Within the blood 
vessels, velocity changes with physiologic variations such as heart rate, respiration, and 
patient condition such as hypertension or anemia (Bolognesi et al., 2006). Multiple 
Doppler signals captured from within the patient should allow the observer to compare 
the velocities of flow in several organs across several Doppler sites. Fluid dynamics will 
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change in the setting of arterial or venous narrowing (referred to as stenosis) or dilatation 
(i.e., aneurysm; Hagen-Ansert, 2006). Examination by Doppler can provide a peak 
velocity or pressure gradient with a great deal of precision by measuring the velocity in 
the center of the vessel of interest (Zweibel & Pellerito, 2005).  
Standardized abdominal Doppler exams currently use only velocity measurements 
(Hagen-Ansert, 2006). By adapting the abdominal software presets to include cardiac 
presets, a velocity measurement was changed to a pressure gradient (mmHg). This 
conversion allowed a fluid comparison between known catheterization venous pressures 
and sonographic Doppler-derived pressure gradients. This protocol provided a rapid 
assessment of the intrahepatic, portal, hepatic, and splenic venous pressures using 
abdominal sonographic techniques. The design of the study sets the stage for future 
research to evaluate the effectiveness of Doppler-derived pressure gradients in 
determining associations between acute liver disease before life-threatening, chronic liver 
changes become manifest.  
Definition of Terms 
The various terms and phrases used in this study were defined as follows: 
Alanine aminotransferase (ALT): An enzyme present in tissues that is slightly 
elevated in patients with acute cirrhosis, hepatic metastasis, and pancreatitis. There is an 
increase in this level in patients with infectious hepatitis and obstructive jaundice (Hagen-
Ansert, 2006).  
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Alcoholic hepatitis: Also known as alcoholic liver disease, alcoholic hepatitis is a 
clinical syndrome of jaundice and liver failure that generally occurs after decades of 
heavy alcohol use (mean intake, approximately 100 g per day; Lucey et al., 2009). 
Ascites: Accumulation of serous fluid within the peritoneal cavity (Hagen-Ansert, 
2006).   
Aspartate aminotransferase (AST): An enzyme present in tissues and associated 
with a high rate of metabolic activity, one of which can be in the liver. Any disease that 
injures the hepatic cells causes an elevation in AST. Significant elevations are present in 
hepatitis and cirrhosis (Hagen-Ansert, 2006). 
Child-Pugh class: Classification of the severity of cirrhosis based on assessment 
of the following variables: encephalopathy, ascites, bilirubin levels, and prothrombin 
time (Sharara & Rockey, 2001).  
Chronicity: Characterized by long duration, the state of being chronic (Chronicity, 
n.d.).  
Cirrhosis: An abnormal liver condition characterized by irreversible scarring of 
the liver. Alcohol and viral hepatitis are among the many causes of cirrhosis (Cirrhosis, 
n.d.; Heymann, 2004). 
Doppler: A change in frequency as red blood cells move from a lower frequency 
sound source at rest toward a higher frequency sound source. Doppler is measured in 
cm/second or m/second (Hagen-Ansert, 2006). 
Echocardiogram: An ultrasound examination of the heart (Hagen-Ansert, 2006). 
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Echogenicity: The strength or amplitude of the reflected echo signal reflected 
using ultrasound. The brighter (whiter) the echo, the greater the echogenicity (Hagen-
Ansert, 2006).  
Esophageal varices: A tortuous dilatation of an esophageal vein, especially in the 
distal portion. This situation results from any condition that causes portal hypertension 
(Venes, 2001). 
FibroTest (FT)®: The biochemical markers registered by Biopredictive and used 
to detect liver fibrosis. Tests include total bilirubin, alpha-2 macroglobulin, 
apolipoprotein A-1, and hemoglobin as well as Biopredictive’s ActiTest®, which 
includes ALT. Values of FT and ActiTest range from 0 to 1.0, with higher values 
indicating a greater probability of fibrosis (Castéra et al., 2009). 
Hepatic encephalopathy: A brain dysfunction present in patients with chronic 
liver disease and portal hypertension, during which chemicals normally detoxified in the 
liver are shunted past the liver and left to circulate in the blood (Venes, 2001).  
Hepatic vein: The vein that takes blood from the liver to the inferior vena cava 
(Venes, 2001). 
Hepatitis: An inflammation of the liver, typically caused by exposure to an 
infectious agent, a toxin, or a drug (Venes, 2001).  
Hepatocytes: Specialized epithelial cells that are the functional parenchymal cells 
of the liver (Tilg & Diehl, 2000). 
Hepatomegaly: An enlargement of the liver (Hagen-Ansert, 2006).  
Hypoalbunemia: The condition of decreased albumin in the blood (Venes, 2001).  
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Liver fibrosis: The excessive accumulation of extracellular matrix proteins 
including collagen that manifests with most types of chronic liver diseases. Advanced 
liver fibrosis results in cirrhosis, liver failure, and portal hypertension, and often requires 
liver transplantation (Rosenberg, 2003). 
Metavir: A liver biopsy scoring system graded on a scale including both the 
fibrosis score from F0 through F4 and the inflammation activity score from A0 through 
A3 (Sharara & Rockey, 2001). 
Modified Bernoulli equation: An equation used to change a velocity measurement 
to a pressure gradient (4V²) using sonographic Doppler techniques; a routine 
measurement used in echocardiography (Lai, Mertens, Cohen, & Geva, 2009).  
Nonalcoholic fatty liver disease (NAFLD): A wide spectrum of liver damage 
ranging from simple steatosis to steatohepatitis or advanced liver fibrosis (Angulo, 2002). 
Portal hypertension: Increased pressure in the portal vein caused by an 
obstruction of the flow of blood through the liver. Portal hypertension is found in 
diseases such as cirrhosis, in which the condition is responsible for ascites, splenomegaly, 
and the formation of varices (Bolognesi et al., 2006).  
Portal vein: A vein formed by the union of veins from the abdominal viscera, 
which then takes blood to the liver. It is made of the combined superior and inferior 
mesenteric, splenic, gastric, and cystic veins (Venes, 2001).  
Pressure gradient (mmHg): The force driving flow through a vessel, measured in 
mmHg. To change a velocity measurement in meters/second to a pressure gradient, the 
modified Bernoulli equation (4V
2
) must be applied (Zagzebski, 1996). 
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Prothrombin: A plasma protein coagulation factor synthesized by the liver that is 
converted to thrombin by prothrombinase and thrombokinase in the presence of calcium 
ions (Venes, 2001). 
Sonography: A high-resolution ultrasound imaging technique used to visualize 
internal organs and vessels in normal and pathological states (Hagen-Ansert, 2006). 
Spectral analysis: A sonographic method used to display Doppler-derived 
velocities using fast Fourier transform. The vertical axis represents the velocity of blood 
in vessels in either a positive or negative direction, or the horizontal axis measures time 
(Hagen-Ansert, 2006). 
Splenomegaly: An enlargement of the spleen (Venes, 2001). 
Splenic vein: The venous drainage from the spleen toward the portal vein (Venes, 
2001). 
Steatosis: The fatty accumulation within liver cells (Hangen-Ansert, 2006). 
Stenosis: Narrowing of a blood vessel caused either by internal blockage (i.e., 
plaque or thrombus) or external compression (i.e., cirrhosis or tumor; Zweibel & 
Pellerito, 2005). 
Telangectasis: A vascular lesion formed by dilatation of a group of small blood 
vessels (Venes, 2001).  
Transient elastography: A noninvasive method to assess liver fibrosis by 
measuring liver stiffness in kilopascals (kPa; Castéra et al., 2008). 
Operational Definitions of Variables 
 The following variables were used in this study. 
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Dependent Variable 
Disease (DISEASE): The dataset was divided into two classifications of those 
patients with (1) or without (0) liver disease.  
Independent Variables 
EchoGrade (ECHOGRADE): The echogenecity of liver, as graded on a scale from 
0 to 3 (Hagen-Ansert, 2006).  
Hepatic venous pressure gradient (HVPG): The intravenous pressure in hepatic 
veins, measured in mmHg. This pressure is measured directly with an intravenous 
catheter or indirectly through a Doppler-derived pressure gradient on an ultrasound 
machine. To record a pressure gradient rather than a velocity, the cardiac preset must be 
applied (i.e., using the Bernoulli equation) to the recorded velocity measurement 
(Zagzebski, 1996). 
Hepatic venous waveform analysis (HVW): Hepatic venous waveform, measured 
by spectral Doppler of the middle hepatic vein. HVW is measured as an ordinal variable 
from 1 to 3 as monophasic, biphasic, or triphasic (Zweibel & Pellerito, 2005). 
Modified portal vein pressure gradient (MPVPG): Calculated pressure gradient 
derived from the measured portal vein diameter divided by the established mean portal 
vein diameter. This is multiplied by the portal vein pressure gradient and the portal vein 
radius to the fourth power to follow the hemodynamic principles of the Bernoulli 
equation (Zweibel & Pellerito, 2005). 
Portal vein diameter (PVD): Portal vein diameter measured with calipers using 
the ultrasound machine caliper function (Hagen-Ansert, 2006).  
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Portal vein pressure gradient (PVPG): The intravenous pressure in portal vein, 
measured in mmHg using the vascular applications of the ultrasound machine (Zweibel & 
Pellerito, 2005).  
Splenic vein pressure gradient (SVPG): The intravenous pressure in portal vein, 
measured in mmHg using the vascular applications of the ultrasound machine (Zweibel & 
Pellerito, 2005). 
Covariates 
Age (AGE): The age range of the data set was between 18 and 75 years. 
Body mass index (BMI): The BMI range of this dataset included all patients with a 
BMI < 35. 
 Ethnicity (E): The ethnicities of the patients were coded as follows:  
White (non-Hispanic), Black (non-Hispanic), Hispanic, and Other. There was a set of 
three dummy variables White (yes = 1, no = 0), Black (yes = 1, no = 0), and Hispanic (yes 
=1, no =0). All others were coded as 0 on all three of these variables.   
Assumptions, Limitations, Scope, and Delimitations 
 Assumptions of the study included the following items: 
 HepC was accurately diagnosed. 
 Patients’ data in this study were representative of a larger population residing 
in the geographic region. 
 Sonography with Doppler can accurately measure pressure gradients. A major 
hypothesis of this study was that there was an association between increased 
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portal, hepatic, or splenic venous pressure gradients, as well as portal vein 
diameter, hepatic venous waveform, or liver echogenecity and liver disease.  
 Based on the literature review, liver disease can lead to cirrhosis and an 
accurate diagnosis of liver disease is essential for timely treatment and a 
positive prognosis.   
 A final assumption was that the literature review, presented in chapter 2, of 
alternative methods including both ultrasound and magnetic resonance-based 
elastography, biochemical markers, and Doppler techniques has accurately 
determined what currently exists and how Doppler-derived pressure gradients 
might assist in predicting the chronicity of liver disease.  
 Limitations, scope, and delimitations of the study included the following items: 
 The study was restricted to the central California geographic area. 
Generalization of the results of the study may or may not relate to geographic 
areas with a similar population base and similar inherent risks for chronic liver 
disease.  
 The study was limited to the variables in the dataset. 
 The study excluded those patients with a BMI > 35 with the exception of 57 
subjects who were included for comparison. 
Significance of the Study 
The health care burden of chronic liver disease is substantial (Bugianesi, 2005). 
This burden includes a financial strain on the health care system, as well as a long 
debilitating illness for the individual patients. The American Gastroenterological 
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Association (as cited in Kim et al., 2002) estimated the economic burden of common 
gastrointestinal and liver disorders including chronic liver disease, chronic HepC, liver 
cancer, and gallbladder disease as accounting for approximately one quarter ($9.1 billion) 
of all direct costs for health care. A review of literature yielded little scientific data to 
support or refute the advantages of alternative screening mechanisms in determining the 
chronicity of liver disease. It was recognized that liver biopsy is invasive, has 
considerable risks, and does not always provide an accurate assessment of the degree of 
liver fibrosis (Castéra et al., 2008) but, due to the lack of other alternatives, liver biopsy 
remains the gold standard for the diagnosis of liver fibrosis leading to cirrhosis (Herrine 
& Friedman, 2005).  
The significance of the study was that the diagnostic method of Doppler-derived 
pressure gradients provided a new approach to determine the relative likelihood of 
someone having liver disease depending on values of the independent variables after 
controlling for all the other variables in the equation. The advantage of developing this 
method was that this method will aid referring physicians to more effectively treat 
patients whose acute liver disease is beginning to progress into chronic liver disease. 
With earlier aggressive treatment and intervention, severe adverse health outcomes 
leading to irreversible liver cirrhosis might be reduced. Prevention of liver disease is not 
always possible, but early intervention and treatment will lead to a decrease in morbidity 
and mortality related to chronic liver disease. This method will provide positive social 
change that could possibly improve the human condition of individuals living with liver 
disease. There was evidence that alternative testing such as the use of fibroelastosis and 
26 
 
 
biochemical markers are helping to predict liver fibrosis (Pickerell, 2010; Ratziu et al., 
2006). This study adds to the current body of knowledge and yielded worthwhile insight 
into the value of an alternative, noninvasive method to determine the chronicity of liver 
disease.  
Summary 
 Chronic liver disease caused by hepatitis, alcoholism, or NALFD is a major health 
problem that results in increased morbidity and greater expenditures of health care dollars 
(CDC, 2005). Alcoholic hepatitis is the third leading preventable cause of death in the 
United States (Lucey et al., 2009), and it is estimated that as many as 70 million 
Americans may suffer from NALFD (Angulo, 2002). There was a need to add to the 
body of knowledge regarding alternative methods to predict the chronicity of liver 
disease.  
Presented in chapter 2 is a literature review covering the current research and 
information on diagnostic tests to detect liver disease, alternative noninvasive methods of 
predicting the chronicity of liver disease, an examination of the ultrasound method 
chosen for this study, and treatment options for chronic liver disease. There is a 
description of the research design and approach offered in chapter 3. The secondary data 
analysis design evaluated the association between increased portal, splenic, and hepatic 
vein pressure gradients as well as assessing the echogenicity of the liver and portal vein 
diameter is detailed. The population of study and the instrumentation and materials 
utilized is described in chapter 3, and the data collection and analysis process is also 
explained. Chapter 3 also discusses the protection of the patient’s rights. Chapter 4 
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provides the results of the analysis of the dataset, and chapter 5 discusses the impact of 
the research as well as the future implications related to this study.   
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Chapter 2: Literature Review 
The conceptual framework of the study was based on an understanding of the 
relationships between liver disease and increased intrahepatic pressures or altered 
imaging characteristics as assessed by sonographic measurements. The review of related 
literature presented in this chapter includes recent studies to evaluate both biopsy 
techniques and alternative methods to predict the chronicity of liver disease, the manner 
in which sonography was used in the diagnosis and prediction of chronic liver disease, 
and how assessment of intrahepatic and splenic blood flow might aid in earlier detection. 
This chapter is organized in sections according to the topics of liver biopsies, biochemical 
screening tests, ultrasound and magnetic resonance-based elastography, and ultrasound 
screening with and without Doppler. Literature about other alternative screening methods 
such as ultrasound-based and magnetic resonance-based elastography and biomarkers 
such as FT® and FibroScan® determine efficacy as compared to invasive liver biopsy 
procedures are presented. Most research on assessing the chronicity of liver disease has 
focused on liver biopsy, which has inherent risks and does not always accurately identify 
the severity of disease. There is a lack of alternative, noninvasive methods and this gap is 
of particular clinical interest. This study determined the value of an alternative 
noninvasive method to predict chronic liver disease. Through the present study, a 
determination of the value of an alternative noninvasive method to predict chronic liver 
disease was sought.   
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Literature Review Strategy 
A literature search tapped various Internet databases such as MEDLINE, 
EBSCOhost, CINAHL, and peer-reviewed journals such as the Journal of Hepatology 
and the New England Journal of Medicine, and government websites such as CDC and 
the World Health Organization. The literature search was performed using keywords 
related to the research questions including viral hepatitis, liver cirrhosis, hepatic, liver 
fibrosis, ascites, elastography, liver biopsy, Metavir, Doppler, alcoholic liver disease, 
nonalcoholic steatohepatitis (NASH), portal vein, splenic vein, hepatic vein, sonography, 
FibroScan®, and FT®. I evaluated each study carefully to determine article content and 
type. Studies were included in this literature review if they were conducted after the year 
2000, if they were primary studies published in peer-reviewed journals dealing with 
hepatology, hepatitis, liver biopsy, or sonographic, and/or alternative techniques for 
assessing the chronicity of liver disease. Meta-analyses of comparative diagnostic 
capabilities were included to increase the researched sample and overall body of 
knowledge. Some textbook references were included due to the perceived value and 
relevance to the topic area of the study. Articles from government agencies and respected 
organizations were reviewed for statistics and supporting information.  
Detection of Liver Disease 
Liver Biopsy 
 The liver biopsy has been the cornerstone of clinical hepatology for many years 
(Sebastiani, 2009). According to Herrine and Friedman (2005), the purpose of performing 
this procedure is to determine which patients are in need of antiviral treatment and, based 
30 
 
 
on the nature and extent of the disease, which patients will likely respond favorably to the 
intervention. An accurate assessment of the severity of liver fibrosis is essential in 
determining when antiviral treatment is recommended (Sebastiani, 2009). Liver biopsy 
remains the gold standard to grading fibrosis; however, it harbors a risk of complications 
including sampling error and inaccuracy due to interobserver and intraobserver variability 
of histopathologic interpretation (Bonekamp et al., 2009). According to Castéra et al. 
(2008), even when an experienced physician performs the biopsy and an expert 
pathologist interprets the results, error rates of up to 20% can occur due to sampling (i.e., 
too small or missed pathology) errors and/or intraobserver variability in reporting the 
fibrosis stage.  
 Liver biopsies are typically reliable for establishing and determining the particular 
type of liver disease, but they are less reliable in determining severity (Goodman, 2007). 
To stage a disease, a determination of the extent of progression toward either organ 
failure or death is needed. The overall goal of staging is the prediction of patient outcome 
(Rosenberg, 2003). There are two simple grading and stage scores for chronic viral 
hepatitis: the Batts-Ludwig and the Metavir (Desmet, Gerber, Hoofnagle, Manns, & 
Scheuer, 1994).  
 Disease status is rated from Grade 0 through Grade 4 according to the Batts-
Ludwig scoring system and from Status A-1 (or F0) through Status A-3 (or F4) according 
to the Metavir scoring system. In both scoring systems, 0 = no fibrosis and 4 = cirrhosis. 
Both systems are widely used and help to identify disease grade and severity and are used 
to quantify the degree of fibrosis. The reliability of these scoring systems is 
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acknowledged as subjective and based largely on the experience of the pathologist 
(Goodman, 2007). Because liver disease scoring systems are semiquantitative and prone 
to intraobserver and interobserver variability, these systems pose limitations. Other 
drawbacks of liver biopsy, in general, are a 20% rate of patient discomfort, 0.1% to 0.3% 
of cases experiencing significant morbidity, and a 0.02% to 0.24% mortality rate (Liu et 
al, 2007).  
 Although a mortality rate of 0.02% to 0.24% was not high compared to that of 
other invasive diagnostic procedures, the study provided an opportunity to further reduce 
the risk by exploring alternative, noninvasive methods. Capture of a small liver sample 
might limit the amount of pathologic tissue and reduce the ability to stage the sample. 
Intervariability within liver samples taken from the same patient has been observed. Even 
when an experienced physician performs the biopsy and an expert pathologist interprets 
the results, there can be to a 20% error rate (Castéra et al., 2008). Because normal 
transaminase values suggest a lack of significant hepatocellular disease, Ratziu et al. 
(2006) proposed that it might be unethical to perform routine liver biopsies on patients 
whose serum transaminase values are in the normal range.  
 In patients with chronic viral hepatitis, the stage of liver fibrosis is the most 
reliable parameter to determine the progression of liver injury, but liver biopsies are 
invasive and present increased risks, especially among those with clotting disorders 
(Bernatik, Stobel, Hahn, & Becker, 2002). The interpretation of biopsies using fibrosis 
stage scoring is problematic because these interpretations are based on qualitative 
descriptors rather than quantitative measure (Rosenberg, 2003). Combination algorithms 
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of noninvasive methods such as TE, biochemical markers, and Doppler parameters have 
been proposed to replace invasive and potentially unreliable liver biopsies in predicting 
the chronicity of liver disease (Herrine & Friedman, 2005). 
Alternative Methods 
 Biochemical markers. An alternative method of predicting liver fibrosis involved 
the use of biochemical markers such as Fibrotest (FT®). Ratziu et al. (2006) conducted a 
study to validate the diagnostic utility of FT in patients with NAFLD. The sample 
consisted of 170 patients with suspected NAFLD who had undergone liver biopsies. All 
patients had either abnormal serum transaminases, steatosis by sonographic criteria, or 
one feature of the metabolic syndrome related to chronic liver disease. Two panel 
markers included ( a) FT with total bilirubin, gamma-glutamyl transferase, Alpha-2 
macroglobin, apolipoprotein A-1, and haptoglobin, corrected for age and gender, as is 
designed for a quantitative assessment of fibrosis; and (b) ActiTest®, which includes 
ALT in addition to the specified markers and is designed for a quantitative assessment of 
histological activity in chronic viral hepatitis. ActiTest encompasses FT and ALT. 
Results indicated that FT was comparable to liver biopsy for advanced liver fibrosis 
(Ratziu et al., 2006). There was 77% sensitivity and 90% negative predictive value for 
advanced fibrosis (FT score of 0.70). ALT levels did not significantly change with 
advancing fibrosis, so ALT levels alone were not a predictor of fibrosis.  
 Many comparison studies have considered the variability of liver biopsies. This 
variability is of clinical significance because all noninvasive tests are compared to an 
imperfect gold standard. Burroughs and Cholongitas (2007) provided a comprehensive 
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comparison of six different noninvasive tests for predicting liver fibrosis including FT, 
Becton Dickinson Fibrometer™, Quest Diagnostic HepaScore™, Forns index, and the 
aspartate aminotransferase/platelet ratio index (APRI). The sample consisted of 180 
biopsies taken from 180 patients with chronic hepatitis. This comparison also included 
noninvasive tests such as ultrasound, computed tomography, Fibroscan®, and Doppler. 
Burroughs and Cholangitas could not confirm the single noninvasive test; however, they 
found that a combination of at least two scores improved the diagnostic accuracy. The FT 
and APRI, when considered together, ruled out significant fibrosis with a negative 
predictive value of 94.1%. The results indicated that an initial liver biopsy might still be 
needed, but subsequent noninvasive tests might be sufficient to follow up for a 
confirmation of fibrosis.  
 Patel et al. (2004) evaluated the diagnostic accuracy of biochemical blood panels 
in patients with chronic HepC to develop a predictive algorithm that differentiates 
between no or mild liver fibrosis (i.e., a Metavir score of F0-F1) and moderate or severe 
liver fibrosis (i.e., a Metavir score of F2-F4). These researchers also sought to validate 
the findings with external cohorts drawn from other facilities. Patel et al. included 596 
patients with chronic hepatitis in their study. Serum samples from healthy volunteers 
served as controls for the serodiagnostic assays. Seven fibrogenesis markers were 
subsequently evaluated blindly in stored serum samples from the initial cohort to enable 
selection the optimal combination of markers to distinguish the various stages of fibrosis. 
Taking into consideration cost, clinical performance, and time, the following three 
markers were selected: HA, TIMP-1, and A2M. The three-marker panel test was used and 
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validated with the external cohort. Including the external cohort, a combined study 
population consisted of 696 patients. The overall area under-the-curve score, sensitivity, 
and specificity were 0.823, 76.9%, and 73.2%, respectively. A positive predictive value 
and accuracy rate of 75% was indicated. The three-marker panel was useful in 
differentiating between relative broad ranges of fibrosis but unable to separate 
intermediate ranges of fibrosis. Liver biopsy was still considered more sensitive in 
predicting liver fibrosis than was biochemical markers, but these markers might still be 
useful when biopsy is contraindicated.   
Transient and Real-Time Ultrasound and MRI Elastography 
 Ultrasound-based TE has been used to detect liver fibrosis in Europe but has yet 
to be approved by the U.S. Food and Drug Administration for use in the United States. 
The one-dimensional technique is used to determine TE—the stiffness of the liver. It is 
best suited for excluding cirrhosis rather than predicting the condition (Bonecamp et al., 
2009). Ultrasound-based TE is helpful in the diagnosis and staging of hepatic fibrosis and 
chronic liver disease, as well as in the detection of subtle liver tumors. The mechanical 
vibrations caused by elastography are proportional to the stiffness of the tissues. This 
technique can differentiate normal or porous liver tissue from tissue that is scarred and/or 
fibrotic (Pickerell, 2010). TE (i.e., Fibroscan®) is a valuable alternative to liver biopsy 
because of its low cost and ease of use, but a specific ultrasound unit must be purchased 
and cannot be used for other sonography procedures. Examination by TE is painless and 
the results are immediately available. A disadvantage of this technique is that accurate 
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measurements are difficult to obtain from obese patients and those with small intercostal 
spaces (Sebastiani, 2009).  
 Castéra et al. (2008) compared Fibroscan® with standard laboratory tests and 
noninvasive scores with the objective of assessing the accuracy of TE for the detection of 
cirrhosis and esophageal varices in patients with chronic HepC, as compared to standard 
laboratory tests (e.g., amino acid racemization, APRI, and platelet count) and noninvasive 
scores (i.e., the FT® and Lok index). TE was performed on the same day as liver biopsies 
on 298 patients and serum fibrosis markers were collected. The diagnostic performance 
of TE was found to be superior in both positive likelihood ratio and area under the ROC 
curve (95% CI) for the diagnosis of cirrhosis. At a cutoff of 14.6 kPa, cirrhosis could be 
predicted with 90% certainty and excluded with 92% certainty. The study by Castéra et 
al. demonstrated that TE is currently the most accurate noninvasive method for the 
detection of cirrhosis, but the rates of correctly identifying patients with esophageal 
varices did not indicate an advantage to using TE as a replacement for endoscopy in 
screening for esophageal varices. Because NAFLD can lead to liver fibrosis and cirrhosis, 
is a potential concern with the use of elastography. Many patients with NAFLD are 
obese, and the failure rate of TE in obese patients ranges between 2.4% and 9.4% 
(Castéra et al., 2008). This failure rate presents a disadvantage compared to magnetic 
resonance elastography (MRE).  
 Real-time sonographic elastography is another method that has been integrated 
with sonography. Sonographic elastography has been applied to many different biopsy 
applications including biopsies of breast, thyroid, cardiac tissue, and liver (Pickerell, 
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2010). An ultrasound transducer probe is mounted on a vibrator. Vibrations are sent into 
the liver. The vibrations of mild amplitude and low frequency (50 Hz) cause an electric 
shear wave to propagate into the liver (Castéra et al., 2008). The returning pulse-echo 
recording measures the shear wave velocity, which is directly related to tissue stiffness, 
and is represented by the following equation for Young’s elastic modulus:  
(E = 3 pv²) 
where v = shear velocity and p = density of the tissue, which is assumed to be constant. 
Dedicated machine-based software determines whether each measurement (measured in 
kPa) is successful (Talwalkar, 2008). TE measures stiffness in a volume that 
approximates a cylinder 1 cm wide and 4 cm long. Because this volume represents a 
much larger sample than the liver biopsy, it is a superior method of detecting liver 
fibrosis when compared to the liver biopsy (Castéra et al., 2008).   
 Similar to ultrasound-based elastography, MRE is another noninvasive method 
that can be used to assess the elastic properties of soft tissues, including the liver 
(Bonekamp et al., 2009). MRE is a relatively new method for staging liver disease and 
more research is needed to confirm or refute the clinical utility of the method. To date, 
there is no commercially available MRE wave-generator device; however, MRE can be 
implemented on standard magnetic resonance systems by using a combination of resistive 
electromechanical drivers, piezoelectric devices, electromagnetic coils, or pneumatic 
drivers. Preliminary results have indicated that the shear elastic properties of the liver 
increased according to the stage of liver fibrosis. Bonekamp et al. (2009) found a 
statistically significant difference between patients with Metavir scores of F0 through F1 
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fibrosis versus those with scores of F2 through F3. The elastic maps of the liver became 
more heterogeneous as the extent of fibrosis increased. Replicability of MRE for 
elasticity and viscosity was good. Of greatest significance, MRE could clearly distinguish 
between the intermediate stages of fibrosis. This feat has proven difficult using 
biochemical testing (e.g., AST: platelet ratio index) in which only advanced fibrosis or 
minimal fibrosis could be separated.   
 Yin et al. (2007) studied the clinical utility of MRE for the detection liver fibrosis. 
MRE was performed on 35 volunteers with healthy livers and 50 patients with biopsy-
proven liver disease. Inclusion criteria included liver biopsy within 1 year, age 18 years 
or older, and/or a diagnosis of compensated liver cirrhosis by histology or combination of 
clinical and imaging criteria. Exclusion criteria included a history of HCC or other liver 
tumor, contraindication for MRI such as surgical clips or a pacemaker, history of liver 
resection or transplantation, and/or decompensating events (e.g., esophageal variceal 
rupture or hepatic encephalopathy). MRE was performed using a 1.5-T whole-body 
imager with a full-body coil. Low-amplitude mechanical waves were introduced into the 
body at 60 Hz. Total acquisition time for the images was 40 seconds. MR elastogram 
images displayed the overall shear stiffness of the liver. The fat: water ratio was also 
obtained using the standard MRI liver-imaging protocol. Yin et al. found that liver 
stiffness correlated very well with fibrosis grades. Analysis of the ROC curve indicated 
that, with a shear stiffness cutoff value of 2.93 kPa, the predicted sensitivity was 98% and 
the specificity was 99% for detecting all grades of liver fibrosis. Yin et al. concluded that 
liver stiffness did not appear to be influenced by the degree of steatosis. 
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 Preliminary results indicated that MRE was a safe and noninvasive method for the 
detection of liver fibrosis. The study by Yin et al. (2007) revealed several advantages to 
MRE over other noninvasive methods for detecting liver fibrosis. These included (a) a 
freely oriented field of view, (b) lack of need for an optimum field of view in contrast to 
TE, (c) compatibility with other MR coils, (d) operator independence, (e) insensitivity to 
body habitus, (f) the concurrent addition of conventional MR at the time of the study, and 
(g) a global view of the entire liver using a multislice method. Additional studies 
involving larger samples will confirm the sensitivity and specificity, as well as the 
diagnostic accuracy of this method.  
Sonographic Imaging Assessment 
 Sonography evaluates liver size, shape, and internal characteristics in a 
noninvasive manner (Hagen-Ansert, 2006). The process uses ultrasound technology to 
determine the presence of chronic liver disease. In the early stages of liver disease, 
sonography is of limited value because the liver parenchymal pattern may appear normal; 
even so, sonography is useful in detecting the late chronic changes associated with 
cirrhosis and HCC (Obrador et al., 2006). Sonographic findings include increased 
coarseness of the liver, nodularity, ascites, and liver mass, if a tumor is present (Hagen-
Ansert, 2006). Coarse hepatic echotexture and mildly increased echogenicity is common 
in cirrhosis (Nicolau et al., 2002). With advanced sonographic equipment, it is now 
possible to detect subtle changes in early liver disease, and the echogenicity can be 
graded from normal to cirrhosis (Hagen-Ansert, 2006).  
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 Obesity may also cause architectural changes in the liver without underlying liver 
disease (Obrador et al., 2006). The liver may become infiltrated with fat and have an 
overall increase in size and echogenicity, confounding the diagnosis of liver fibrosis 
(Rumack, Wilson, & Charboneau, 2005). Fatty infiltration can be graded sonographically 
from 1 to 3 (Hagen-Ansert, 2006). At Grade 1, a slight increase in coarseness and 
echogenicity of the liver parenchymal pattern is typically noted (Hagen-Ansert, 2006), 
but the diaphragm and intrahepatic vessels can still be seen. At Grade 2, moderate 
increase in the coarseness and echogenicity of the liver is noted (Hagen-Ansert, 2006). 
Because of attenuation (i.e., weakening of the sound beam), the sound beam experiences 
more difficulty in penetrating the liver and there is evidence of decreased visualization of 
the diaphragm and intrahepatic vessels (Hagen-Ansert, 2006). At Grade 3, a marked 
increase in coarseness and echogenicity either with poor or absent visualization of the 
diaphragm and intrahepatic vessels is noted (Hagen-Ansert, 2006).    
 Fatty infiltration is reversible because the individual hepatocytes are filled with 
fat (Tilg & Diehl, 2000). Changes in diet or cessation of alcoholic beverages can reduce 
the fatty content and return the liver to a relatively normal and homogeneous texture. 
Once the liver has become fibrotic and the parenchyma degenerates, as seen in cirrhosis, 
the process is irreversible (Hagen-Ansert, 2006). Another sonographic measurement 
useful for predicting cirrhosis is the caudate: right lobe ratio (Goldberg & McGahan, 
2006). When the liver becomes fibrotic, the right and left lobes tends to shrink more than 
the caudate lobe (Goldberg & McGahan, 2006). This disparity is due to the dual arterial 
blood supply to the caudate lobe. The ratio compares the transverse diameter of the 
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caudate to the right lobe in a transverse imaging plane. Goldberg and McGahan (2006) 
proposed a cutoff ratio of 0.65 after finding the proposed ratio of 0.65 or greater had a 
sensitivity of 84% and a specificity of 100%. 
Portal Vein Diameter 
 An association exists between an increased portal venous diameter with liver 
cirrhosis and portal hypertension (Nicolau et al., 2002). The extent to which this 
association is a predictor of liver fibrosis has not been determined. The portal vein is 
easily visualized when liver texture is homogeneous, but becomes difficult to see with 
advanced fatty infiltration of the liver (Rumack et al., 2005). A measurement threshold of 
13 mm in diameter is a predictor of portal hypertension in patients with cirrhosis (Hagen-
Ansert, 2006). The present study explored the portal venous diameter (PVD) by gender 
(G) and by liver echogenicity grades (ECHOGRADE), as assessed by real-time 
sonography.  
 In a study conducted by Weinreb, Kumari, Phillips, and Pochaczevsky (1982), the 
right portal vein was measured in an anterior-posterior plane near the porta hepatis where 
the portal vein enters the liver. Of particular interest was whether the change in diameter 
would affect the overall pressure gradient. Weinreb et al. determined the normal portal 
vein diameter measurement on 107 patients, aged 21-40 years, is 11 +/- 2 mm. According 
to a known hemodynamic law, Poiseuille’s law, the radius of the vessel has the largest 
effect on flow (Celli, 1997). Poiseuille’s law states that the volume of fluid passing per 
unit time through a tube is directly proportional to the pressure gradient multiplied by the 
fourth power of the radius of the tube (Daugherty & Franzini, 1977). A more exact 
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method of computing the blood flow through the portal vein could be conducted by 
calibrating Poiseuille’s model: 
  
where V = the volume of blood (m
3
), t = the time (sec), dV/dt = the flow rate of the blood 
(m
3
/sec), R = the radius of the vein (m), η = the dynamic fluid viscosity of the blood 
(Pascal.sec), ΔP = the pressure gradient (Pascals), and L = the length of the vein (m). 
 The radius of the vein has such a large effect on flow, and in the setting of 
cirrhosis, the portal vein is dilated (Hagen-Ansert, 2006). This study suggested applying a 
mathematical modifier based upon the difference in diameter in patients with cirrhosis or 
chronic liver disease and compared to the known median diameter of a portal vein in a 
healthy liver. For example, if the known median diameter of the portal vein in a healthy 
liver is 1.1 cm and the portal vein diameter of a patient with cirrhosis is 2.2 cm, then the 
following mathematical modifier may apply: 
Measured pressure gradient (PVPG) x Portal vein ratio (PVR)  
x (diameter of the portal vein x 0.5)
4
. 
In the example, assuming the measured pressure gradient was 2 mmHg, then the 
calculation for the modified pressure gradient would be as follows: 
(2 mmHg) (2) (2.2 x 0.5)
4 
= 5.4 mmHg 
 Portal vein ratio (PVR) would equate to the multiple of the mean that was 
determined from the known normal portal vein diameter. This modified portal vein 
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pressure gradient (MPVPG) more closely aligns with the pressure gradients found in 
endoscopy measurements (Sharara & Rockey, 2001).  
Doppler Assessment 
In addition to real-time imaging of the liver by sonography, complimentary 
techniques can improve the diagnostic capabilities, including duplex Doppler, color 
Doppler, power Doppler, ultrasound contrast agents, and harmonic imaging (Nicolau et 
al., 2002). In the liver, the portal and hepatic veins were evaluated with both color and 
spectral Doppler. Color Doppler displays color-coded information over the two-
dimensional image to determine the presence and direction of the blood flow. The mean 
velocity of the red blood cells circulating into and from the liver was displayed. Blood 
flowing toward the transducer is indicated in red and blood flowing away from the 
transducer is coded as blue (Rumack et al., 2005). Flow travels toward the liver in the 
portal vein and away from the liver in the hepatic veins (Hagen-Ansert, 2006). Using 
standardized protocol, color Doppler of the portal vein was indicated in red and hepatic 
venous flow was indicated in blue.  
Although color Doppler is advantageous in determining the presence and 
direction of blood flow, it is not considered a quantitative process because it lacks the 
ability to calculate the peak velocity. Spectral Doppler is the accepted method for 
determining the peak velocity and/or pressure gradient. It allows the sonographer to place 
a sample volume (gate) at a specific point inside the vessel. The peak velocity was 
measured over time. This technique produces a waveform including the peak velocity, 
pressure gradient, and waveform analysis. In this study, the modified portal vein pressure 
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gradient (MPVPG), portal vein pressure gradient (PVPG), hepatic venous pressure 
gradient (HVPG), and splenic vein pressure gradient (SPPG) were in the dataset as well 
as the hepatic venous waveform (HVW) analysis.   
With liver fibrosis or cirrhosis, the liver texture becomes hardened and the flow 
within the vessels responds to the change in texture. The hepatic veins are usually 
multiphasic from the movement of the tricuspid valve annulus toward the heart apex, 
atrial overfilling, tricuspid valve opening, and the atrial contraction (Goldberg & 
McGahan, 2006). When the liver hardens, the hepatic veins can become compressed and 
show a more continuous flow pattern. Hardening of the liver may also trigger reversed 
flow in the portal vein, causing blood to take a collateral pathway from the liver to return 
blood to the inferior vena cava. This condition is portal hypertension (Rumack et al., 
2005). Both color Doppler and spectral Doppler is invaluable in determining the 
intrahepatic blood flow hemodynamics. Velocity measurements alone have never been 
standardized (Goldberg & McGahan, 2006).   
In this study, the method of testing was to translate the data from the acquired 
data set in pressure gradients instead of velocity measurements. Using Doppler criteria of 
pressure gradients instead of velocity measurements will help to establish a cutoff point 
at which the liver is changing from fatty infiltration to liver fibrosis. To change a velocity 
measurement, the Bernoulli equation was applied. The estimation of pressure differences 
between two anatomic structures is one of the most common applications in 
echocardiography (sonography of the heart). The modified Bernoulli equation states that 
the change in pressure is equal to 4 multiplied by the velocity squared (4V²; Lai et al., 
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2009). By applying the cardiac presets (Bernoulli equation) to the abdominal Doppler 
velocity measurements, these pressure gradients can be determined noninvasively. This 
method was used when acquiring the data set. The dataset values were retrospectively 
altered by applying a mathematical modifier, taking into account the increase in portal 
vein diameter with advancing liver disease.    
 A few noteworthy studies have focused on the association of early liver fibrosis 
with Doppler-derived measurements. Doppler ultrasonography is a valuable noninvasive 
method useful in the study of intrahepatic hemodynamics in liver disease (Bernatik et al., 
2002). Bernatik et al. (2002) compared Doppler parameters of the portal vein, hepatic 
artery, and hepatic vein in patients with different stages of liver fibrosis. Their study 
included 43 patients with biopsy-proven chronic viral hepatitis without cirrhosis. All 
patients had elevated ALT and AST levels. Patients with a history of chronic alcoholism 
were excluded from the study. Both the maximum and mean velocity was measured in 
the portal vein. The resistive index was measured in the hepatic artery. Results indicated 
that with severe fibrosis and cirrhosis, there were hemodynamic changes in the hepatic 
vein (biphasic or monophasic) and increased resistance in the hepatic artery (Bernatik et 
al., 2002). In early liver fibrosis, the addition of Doppler parameters was not of clinical 
significance in assessing the stage of liver fibrosis or for differentiating mild fibrosis 
from severe fibrosis.  
 In another study involving 565 consecutive patients with chronic liver disease, 
Liu et al. (2007) used splenic arterial pulsatility index (SAPI) and portal vein mean 
velocities to evaluate the severity of hepatic fibrosis before liver biopsy. Using 
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multivariate logistic regression, it was revealed that the SAPI and the mean portal vein 
velocity were predictive of significant fibrosis and cirrhosis. Specifically, the predicted 
probability of patients having significant hepatic fibrosis and cirrhosis was a function of 
increased SAPI and decreased portal vein mean velocities (Liu et al., 2007). The mean 
velocity of the portal vein was decreased as the level of liver fibrosis increased. A 
possible explanation for this phenomenon is that, as the liver becomes more nodular, the 
intrahepatic venous flow may take the path of least resistance. It may be easier for the 
blood to follow collateral channels rather than course through a nodular liver. As 
collateral venous flow increases, the amount of flow traversing the liver may was 
reduced. This change in blood flow through the liver would result in lower portal venous 
velocity (Liu et al., 2007).  
 O’Donohue, Ng, Catnach, Farrant, and Williams (2004) investigated the clinical 
utility and diagnostic value of measuring the splenic size, portal vein velocity, hepatic 
venous profile, and hepatic arterial resistance in a cohort of 49 controls and 45 patients 
with biopsy-proven liver disease. Of all of these variables in their study, the only 
predictive value for liver fibrosis or cirrhosis was increased splenic size (> 15 cm) and an 
abnormal hepatic venous profile. Doppler parameters of portal vein velocity, portal vein 
diameter, and hepatic arterial resistive index were no different between the controls and 
patients or between cirrhotic and noncirrhotic liver disease. A possible limitation to this 
study was the small sample size of only 45 patients with liver disease and 49 controls. 
 Dietrich et al. (1998) analyzed Doppler spectral waveforms in 135 patients with 
chronic HepC. Spectral waveforms were analyzed in the right hepatic vein as well as the 
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portal vein velocity. Although previous studies (Bernatik et al., 2002; O’Donohue et al., 
2004) had suggested that the change in normal triphasic waveform to monophasic was 
caused by liver fibrosis, the study by Dietrich et al. concluded that intrahepatic fat 
deposition was associated with this change more than was liver fibrosis or cirrhosis. 
There did not appear to be a distinct difference in the Doppler waveform of the hepatic 
vein in the setting of fibrosis and cirrhosis. A pronounced pulsatility in the portal vein 
was associated with portal inflammation. In the setting of cell death, as seen in cirrhosis, 
there is an inflammatory reaction. This cell death evokes an inflammatory reaction (portal 
inflammation) that is morphologically manifested by the appearance of inflammatory 
cells, together with edema and congestion around the damaged hepatocytes (Dietrich et 
al., 1998).  
 Barbaro et al. (2000) researched the correlation of MRI liver volume and Doppler 
sonographic portal hemodynamics with the histologic liver biopsy findings in patients 
with chronic HepC. The ratio between portal blood flow and liver volume determined the 
portal flow index (PFI) of the right and left lobes. The results reported by Barbaro et al. 
indicated that an elevation in the volume of the left hepatic lobe and a reduction in the 
left PFI might help to diagnose patients with chronic HepC and that the postprandial left 
PFI might also help to differentiate the degree of fibrosis. The three lobes of the liver 
(right, left, and caudate) are functionally different. The right lobe receives blood mainly 
from the superior mesenteric vein, the left lobe receives more blood from the splenic 
vein, and the caudate lobe receives blood from both sources (Hagen-Ansert, 2006). This 
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difference occurs in all individuals, not just those with liver disease. This information 
provided the rationale for the difference in right and left portal venous indices.  
 Berzigotti et al. (2005) remarked that propranolol and nadolol decrease hepatic 
venous pressure in patients with cirrhosis whose esophageal varices were at risk for 
bleeding. The study included Doppler analysis of the portal vein, superior mesenteric 
artery, splenic artery, and hepatic artery. Pulsatility index and resistive index 
measurements were obtained on the arteries and the mean velocity of the portal vein and 
portal vein diameter was recorded (Berzigotti et al., 2005). These Doppler parameters 
were compared to endoscopy-recorded HVPG pre- and posttreatment with the beta-
blocker nadolol. Results indicated that with proper response, nadolol induces splanchnic 
(intestinal vessel) vasoconstriction and reduction of HVPG, but in patients with 
splanchnic vasodilatation in the baseline study, there was a reduced response to treatment 
with beta-blockers. HVPG repeat measurements were recommended to continually 
monitor the response of the treatments. 
 Liu et al. (2007) explored hepatic artery and splenic artery resistance in the setting 
of advanced liver disease. In a healthy person, the liver and spleen are considered a low-
resistance vascular bed. To illustrate this point, both the liver and spleen are organs that 
require blood throughout the cardiac cycle, both in systole and diastole. As a result, the 
Doppler waveform in these arteries displays a fair amount of diastolic flow. When the 
liver becomes fibrotic, the liver function starts to decrease (Guthrie, 2008). In organ 
failure, the blood flow pattern changes as a reflection of flow demand to a nonfunctioning 
or poorly functioning organ. The body adapts and only provides flow to perfuse the organ 
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as a tissue instead of as a viable organ. In this setting, there is little or no flow in diastole 
and the resistive indices in these arteries increase. This situation is much like the flow to 
extremities. Arms and legs do not require flow throughout the cardiac cycle because they 
are not organs. Only in the setting of exercise, when the oxygen demand increases, is 
there a substantial flow in diastole. Organs should never exhibit flow like that seen in the 
extremities (Guthrie, 2008). The study by Liu et al. exemplified this point. In the setting 
of chronic liver disease, specifically liver fibrosis and cirrhosis, diastolic flow increased. 
This change in diastolic flow raised the SAPI. Liu et al. concluded that the SAPI was 
accurate in predicting both significant liver fibrosis and cirrhosis, with under-the-curve 
scores of 0.87 and 0.90, respectively. The change in under-the-curve scores means that 
the normal SAPI falls below 0.87 for fibrosis and 0.91 for cirrhosis. Additionally, the 
lower the SAPI, the more flow that goes to the organ through increased diastolic flow.    
Liver fibrosis is a known cause of regional hepatic and systemic hemodynamic 
changes (Bolognesi et al., 2006). Bonekamp et al. (2009) aimed to determine if imaging 
modalities could diagnose and stage hepatic fibrosis and cirrhosis accurately. A systemic 
review of 628 studies that compared ultrasonography with elastography was performed. 
The inclusion criteria were studies that were written in either English or German; used 
liver biopsy as a reference; reported sensitivity, specificity, and diagnostic accuracy; or 
described a completely new imaging approach (Bonekamp et al., 2009). Studies were 
excluded if they did not use liver biopsy as a reference or if they had a very small sample 
size.  
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In the analysis reported by Bonekamp et al. (2009), the study by Hirata, Akbar, 
Horiike, and Onji (as cited in Bonekamp et al., 2009) found a lack of consistency in 
determining the best ultrasound markers for liver fibrosis or cirrhosis. The hepatic 
parenchymal pattern and splenic size were helpful in determining cirrhosis, but not 
necessarily discriminating between fibrosis and cirrhosis (Hirata et al., as cited in 
Bonekamp et al., 2009). Bonekamp et al. found that the published data on Doppler 
ultrasound in liver fibrosis was quite limited, showed a lack of reproducibility, and the 
results were contradictory. A study by Bolognesi et al. (as cited in Bonekamp et al., 
2009) suggested that ultrasound and Doppler ultrasound were helpful in determining liver 
cirrhosis, but not (yet) clinically useful for assessing the stage of liver fibrosis.  
Endoscopy Prediction of Variceal Hemorrhage 
Cirrhosis is the most common cause of portal hypertension (Bolognesi et al., 
2006). Portal hypertension in conjunction with liver fibrosis/cirrhosis increases the 
chance of morbidity or mortality. Portal hypertension occurs when the intrahepatic 
venous pressure exceeds systemic pressure, allowing the normal hepatopetal blood flow 
toward the liver to reverse and take a path of lesser resistance. Varices are portosystemic 
collaterals formed after preexisting vascular channels are dilated secondary to portal 
hypertension (Sharara & Rockey, 2001). Although there is a high prevalence of varices in 
patients with cirrhosis, only about one third of the patients will actually develop varices. 
Screening endoscopy determines the presence and size of the varices. Endoscopy 
predicts variceal hemorrhage by visualization of large varices and endoscopic red signs 
(e.g., red wale markings) of the variceal wall. Gastroesophageal variceal hemorrhages are 
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a major complication of portal hypertension associated with a significant increase in 
morbidity and mortality. Up to 30% of initial ruptures are fatal, and it is estimated that up 
to 70% have recurrent bleeding (Sharara & Rockey, 2001). Because gastroesophageal 
rupture is the most severe complication of cirrhosis, it is necessary to determine not only 
if a patient has varices, but also which patients are at highest risk for rupture.  
Performing upper gastrointestinal endoscopy as a screening process on every 
patient with cirrhosis would result in many unnecessary tests. A noninvasive method 
would be helpful in identifying patients with varices before endoscopy. A low platelet 
count is seen in patients with varices. Other prognostic factors for varices include a portal 
vein diameter greater than 13 mm, advanced Child-Pugh class, hypoalbuminaemia, 
telangiectasis, low prothrombin activity, and splenomegaly.  
 To predict the presence or absence of varices, a model was developed using a 
combination of laboratory results and portal vein diameter. This model included a platelet 
count of < 100,000/mm, portal vein diameter > 13 mm, and a prothrombin activity of 
< 70% (de Franchis, 2003). However, when this model was tested, it was found to have 
poor sensitivity and specificity. Specifically, 42% of the patients in the study who were 
classified by this model as having varices had none, and 34% who were scored at low 
risk had varices (de Franchis, 2003). Regarding endoscopy findings, the presence of red 
wale markings on varices identified using the initial endoscopy was the only true 
predictor of bleeding. The 2-year bleeding rate was higher on those with small varices on 
the initial endoscopic exam than on those without varices and that those with an alcoholic 
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etiology for cirrhosis tended to have a higher risk of developing varices (de Franchis, 
2003).  
 Although the idea of using alternative methods for predicting the presence or 
severity of varices seems promising, to date it has not proven reliable. Screening 
endoscopy remains the test of choice for detection and progression of gastroesophageal 
varices. The addition of catheterization of the right hepatic vein to determine the pressure 
gradient has increased the sensitivity and specificity of identifying the risk of variceal 
rupture. The proposed sonographic Doppler-derived pressure method using the Bernoulli 
equation to obtain a pressure gradient (in mmHg) is hypothesized to be comparable to 
catheterization of the right hepatic vein in the ability to detect increased right hepatic 
venous pressure and consequently the risk of variceal rupture. 
Statistical Methodology in the Study 
I used logistic regression to analyze the data in this study. Logistic regression 
constructs models by using an iterative procedure known as a maximum likelihood 
method that cycles through many repetitions to find the best fit to the data. In addition, an 
odds ratio (OR) was computed for each X variable (Hosmer & Lemeshow, 2000). The 
calculation of the OR permits the likelihood of a specified outcome (e.g., the presence of 
disease) to be compared between two different groups of patients.  
ORs computed using logistic regression are sometimes misinterpreted by medical 
researchers because the ratios might be confused with relative risks (Dawson & Trapp, 
2004). For example, Moss, Wellman, and Corsonsis (2003) reported that 40% of the 
articles they reviewed in the medical literature did not interpret the results of logistic 
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regression appropriately. A detailed explanation of the OR is provided here. The OR and 
the relative risk (sometimes called the risk ratio) both compare the likelihood of an event 
(e.g., the presence of a disease) between two groups; however, the OR compares the 
odds, whereas the risk ratio compares the probabilities. Odds and probability are not 
equivalent. The probability of a patient having a disease is equal to the number patients 
with the disease divided by the total number of patients in the sample. The odds of a 
patient having a disease are the number of patients with the disease divided by numbers 
who do not have the disease.   
Odds and probability are closely related using two formulae:  
Odds = probability/(1 - probability) and probability = odds/(1 + odds) 
The odds ratio for an independent (X) variable in a logistic regression equation is the 
antilogarithm of its regression coefficient. The odds ratio of X predicts the likelihood of 
the outcome changing from one category to another category, in response to a 1-unit 
change in the value of X. If OR = 1.0, then X has no effect on the dependent variable. If 
OR > 1.0, then an increase in X elevates the likelihood of a change in the dependent 
variable. If OR < 1.0, then an increase in X elevates the likelihood of a change in the 
dependent variable (Hulley et al., 2001). 
A hypothetical example clarifies the interpretation of the odds ratio. Consider a 
binary logistic regression model comprising a dependent variable with two categories, 
coded 0 and 1 (where 0 represents a group of healthy patients without liver disease, and 1 
represents a group of patients diagnosed with liver disease); X is the PVD (cm) and OR = 
3.0. The interpretation of the odds ratio is that if the PVD of a patient expands by 1.0 cm 
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(e.g., from 1.0 cm to 2.0 cm), then the likelihood of a patient having liver disease will be 
3 times greater than the likelihood of a patient not having liver disease. For n units of 
change in X, the log odds changes by OR
n
. This relationship implies that if the diameter 
of the portal vein expands by 2.0 cm (e.g., from 1.0 cm to 3.0 cm), then the likelihood of 
a patient having liver disease is 3.0
2
 = 9 times greater than a patient not having liver 
disease. 
Logistic regression is much less restrictive than linear regression. Unlike linear 
regression, the variables do not have to be normally distributed, linearity between the 
dependent and independent variables is not assumed, and the variance in the dependent 
variable does not have to be equal across all the independent variables (Hosmer & 
Lemeshow, 2000). Logistic regression does, however, assume that excessive 
multicollinearity is not present (i.e., the independent variables must not be too highly 
correlated with each other). If excessive multicollinearity occurs, then the logistic 
regression coefficients and the odds ratios are biased and the overall model becomes 
difficult, if not impossible, to interpret. The computed modified portal vein pressure 
gradient incorporates both the portal vein diameter and the portal vein pressure gradients. 
This pressure gradient suggests that there may be at least a moderate multicollinearity. If 
after logistic regression, excessive multicollinearity was suspected, a test of the 
relationship of these independent variables was performed. The modified portal vein 
pressure gradient was used in the final model. ROC was used to determine the probability 
of liver disease based on the independent variables (sonographic measures). ROCs were 
generated on only the specific independent variables that show a statistically significant 
54 
 
 
correlation between the independent variable and liver disease. Because each of the 
independent variables in this study are diagnostic tests, independent of each other, ROCs 
are an efficient way to display the relationship between sensitivity and specificity for 
tests that have continuous outcomes (Lang & Secic, 1997). The ROC is a plot of the 
sensitivity (true positives) relative to the false positive rate (Dawson & Trapp, 2004). The 
closer the proximity of the ROC to the upper left-hand corner of the graph, the more 
accurate the ROC is. In this study, the ROC was used to determine the true positives to 
the false negatives only on the specific independent variables that showed statistical 
significance by the multiple logistic regression analysis to predict liver disease. The 
original design was to include another category of independent variables including 
STATUS of disease. The independent variable shown in Table 1 was considered under 
the heading of STATUS: 
 
Table 1 
 
Independent Variable Considered Under Original Design 
STATUS 
 
 
 
 
Presence of a specified 
type of liver disease 
Nominal 0 = liver disease is absent 
1 = gallbladder (GB) disease 
2 = nonalcoholic steatohepatitis (NASH) 
and nonalcoholic fatty liver disease 
(NAFLD) 
3 = hepatitis 
4 = cirrhosis and ascites  
 
A logistic regression model must be specified with respect to the measurement 
level of the dependent variable. In a binary logistic regression model, the dependent 
variable is dichotomous, representing two possible categories, coded in binary form with 
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0 and 1, where 0 = a reference category (e.g., disease is absent) and 1 = an observed 
outcome (e.g., disease is present). Binary logistic regression was therefore appropriate for 
this study using DISEASE as the dependent variable. The model of STATUS was 
proposed due to curiosity as well as the opinion that the research would be more 
meaningful if the independent variables could predict not only disease or no disease, but 
also the specific type of disease. In a nominal logistic regression model, the dependent 
variable represents three or more numerically coded qualitative categories (e.g., 0 = liver 
disease is absent; 1 = gallbladder (GB) disease; 2 = nonalcoholic steatohepatitis (NASH) 
and nonalcoholic fatty liver disease (NAFLD); 3 = hepatitis; 4 = cirrhosis and ascites) 
but no implicit hierarchy or order is implied by the codes. Nominal logistic regression 
was therefore appropriate for this study using STATUS as the dependent variable. 
However, the maximum likelihood or optimization algorithm may be limited when more 
than one independent variable is included (Hosmer & Lemeshow, 2000). For this reason, 
it was decided to forego STATUS as a dependent variable. However, after the analysis 
was performed, STATUS may be reintroduced for future studies. This model used the 
independent variables that populate a statistically significant correlation in predicting 
chronic liver disease using the binary logistic regression model of DISEASE.    
Summary 
 The review of related literature presented in this chapter included recent studies to 
evaluate both biopsy techniques and alternative methods to predict the chronicity of liver 
disease, the manner in which sonography is used in the diagnosis and prediction of 
chronic liver disease, and how assessment of intrahepatic and splenic blood flow might 
56 
 
 
aid in earlier detection. This chapter was organized in sections according to the topics of 
liver biopsies, biochemical screening tests, ultrasound and magnetic resonance-based 
elastography, and ultrasound screening with and without Doppler. Literature about other 
alternative screening methods such as ultrasound-based and magnetic resonance-based 
elastography and biomarkers such as FT® and FibroScan® were reviewed relative to 
efficacy as compared to invasive liver biopsy procedures. Ultrasound and Doppler 
techniques are helpful in determining the presence of fatty infiltration of the liver or 
cirrhosis, ascites, portal vein diameter, and flow direction in the hepatoportal system 
(Hagen-Ansert, 2006). Further research was needed to determine if portal, hepatic, or 
splenic vein pressure gradients could assist in predicting chronic liver disease. The 
specific research design and methodology related to testing this noninvasive method in 
detecting liver disease as an extension of research reviewed in this chapter is presented in 
chapter 3.  
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Chapter 3: Research Methodology 
Chapter 3 presents the research design and approach, sample population and size, 
screening criteria, and study variables for the study. The research methodology included 
performing a secondary data analysis of a data set that included 546 patients who 
received an abdominal sonogram at a medical facility in the western United States 
between March 2010 and December 2010. As there were 10 patients with missing data, 
the data set included 536 patients. This data set included the dependent variable 
(DISEASE) and the independent variables of liver echogenicity, portal vein diameter, and 
portal, modified portal, splenic, and hepatic venous pressure gradients. All information 
included in the data set had no patient identifiers. Binary logistic regression compared all 
independent variables with the dependent variable DISEASE to determine if any or all of 
the independent variables could noninvasively predict liver disease. The implication for 
social change was that if a noninvasive sonographic marker can be developed to predict 
individuals at risk for chronic liver disease, based on the analysis of the data, then 
interventional procedures such as earlier medical treatment might be performed before 
portal hypertension leads to irreversible damage to the liver and other organs. 
Additionally, if liver disease is detected earlier, the health care costs associated with 
providing care and services to those with chronic liver disease will decrease.  
 Many studies have proposed noninvasive tests to replace liver biopsy (Barbaro et 
al., 2000; Bernatik et al., 2002; Liu et al., 2007; Obrador et al., 2006; Sebastiani, 2009). 
These studies examined either a single biochemical marker or a combination of 
biochemical markers and other noninvasive imaging. The overarching goal of this study 
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was to develop a sonographic screening method that will predict chronic liver disease 
using Doppler-derived pressure gradients.  
Research Design and Approach 
The study included statistical analysis of an existing data set. The exact method 
and equipment used in data collection appears in Appendix A. The data set includes the 
following data: gender; race/ethnicity; portal vein diameter (in cm); liver echogenicity 
grade; portal vein, hepatic vein, and splenic vein pressure gradient (in mmHg); hepatic 
vein waveform analysis; and disease status. The cross-sectional study design allows for 
the use of standardized sonographic protocols in the patient population referred for 
abdominal sonograms. No additional sonographic information was added to the 
traditional abdominal sonographic protocol. A cross-sectional design refers to a study that 
is conducted at a single point in time (Creswell, 2003). The research involved analyzing 
the data set recorded from the abdominal sonograms.  
Sample Selection and Size 
The sample in the data set was drawn from residents of Fresno and Madera 
counties in central California and nonresidents who received their care at a health care 
center in the western United States. The sample includes individuals who received care 
from March 2010 to December 2010. The majority of these individuals are residents of 
the two counties. According to the U.S. Census Bureau (2006), the estimated population 
in these two counties in 2006 was 1,041,130. This geographic area is an economically 
depressed region of the United States. For the time period during which the data set was 
generated, Fresno County reported 13.9% of families living below the poverty level and 
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17.8% of individuals living below the poverty level; Madera County reported 16.5% of 
families living below the poverty level and 21.2% of individuals living below the poverty 
level. These poverty levels are notably higher than the national average of 9.6% and 
13.2%, respectively (U.S. Census Bureau, 2006).  
The U.S. Census Bureau (2006) reported race/ethnicities for the area as follows: 
61.3% Caucasian or European American, 5.1% Black or African American, 48.2% 
Hispanic or Latino, 8.7% Asian, 1.1% American Indian and Alaska Native, and less than 
0.1% Native Hawaiian and Other Pacific Islander. These statistics suggest that some of 
the Hispanic and Latino population did not mark any race. The dataset represented the 
same relative ratio of race/ethnicity as reported in this geographic region. The reported 
median household income was $45,805. The median age of residents in the two counties 
was 30.1. Of the population in the area under study, 50.4% were men and 49.6% were 
women (U.S. Census Bureau, 2006). These residents represent the individuals who are 
included in the data set.  
The participants represented in the data set include both men and women between 
the ages of 18 and 70, as well as all racial and ethnic groups. Exclusionary criteria for 
analysis were those with known hepatocellular carcinoma, congestive heart failure, blood 
clotting disorder, or morbid obesity (BMI > 35), as recorded in the data set at the time of 
the abdominal sonogram. Demidenko (2007) reviewed various methods of analysis 
suitable for computing the minimum sample size for logistic regression analysis and 
concluded that there is no consensus on the best method. Consequently, several 
approaches are applied here to determine the sample size requirements for this study. 
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 According to Long (1997), the absolute minimum sample size for binary logistic 
regression analysis is 100 cases. According to Hosmer and Lemeshow (2000), binary 
logistic regression requires a minimum of 10 and preferably 30 or more cases for each 
independent variable. In this study, there were potentially up to seven independent 
variables (PVD, PVPG, MPVPG, HVW, SVPG, HVPG, and ECHOGRADE); therefore, 
the minimum sample size is between 70 and 210. According to Peduzzi, Concato, 
Kemper, Holford, and Feinstein (1996), the absolute minimum sample size for binary 
logistic regression is N = (10k) / p where k = the maximum number of independent 
variables and p = the probability of expected events in the dependent variable. In this 
study, the maximum number of independent variables = 7 and the expected prevalence of 
liver disease = .6. Consequently the minimum sample size is (10 x 7) / .6 = 117. Finally, 
power analysis was performed using G*Power 3.1.2 software (Erdfelder, Faul, & 
Buchner, 1996). The input parameters for a two-tailed test were expected prevalence of 
liver disease = .6; expected odds ratio = 1.5, significance level = .05 and power = .8. The 
computed minimum sample size = 215.  
 The sample size used in this study, extracted from a database containing 536 
cases, reduced to 478 with the removal of those with a BMI greater than 35, was in 
excess of the minimum required sizes. I also stratified the sample using the variable of 
gender before using logistic regression analysis to adjust for other confounders. Because 
the male/female ratio was approximately 1:1, the available sample size remained 
adequate for the purposes of logistic regression analysis. 
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Screening Criteria 
 Screening criteria can either directly or indirectly affect the results of a study. 
Obesity is a confounder for echogenicity of the liver. As BMI increases, the liver tends to 
become fat-infiltrated. Patient BMI information was included in the data set. Obese 
patients (BMI 25-35) were included and morbidly obese (BMI > 35) were excluded from 
the study. A fat-infiltrated liver appears more echogenic (i.e., whiter than a normal liver) 
on the image (Hagen-Ansert, 2006). This appearance may mimic that of early liver 
fibrosis and may be indistinguishable by sonographic imaging alone. Venous pressure is 
increased in congestive conditions such as congestive heart failure and severe tricuspid 
regurgitation. Those patients with known congestive heart failure by report were 
excluded from the study, but it was assumed that not all patients referred for abdominal 
sonograms were aware of having an underlying cardiac disease.  
Study Variables  
Dependent variable. There was one dependent variable in this study. The 
dependent variable, DISEASE, divided the sample of patients into two mutually 
exclusive groups according to whether or not the patients were diagnosed with liver 
disease. DISEASE was coded in binary format, where 0 = disease is absent and 1 = 
disease is present (see Table 2). The information used to validate the dependent variables 
was based on the medical records for each patient, including the results of liver function 
tests (e.g., AST and ALT). 
Variables. The dependent and independent variables are listed in Table 1.  
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Table 2 
 
Dependent and Independent Variables 
Variable Definition Level 
Groups/Units/Codes/
Measures 
Dependent variable 
DISEASE Presence of liver disease  Nominal 0 = liver disease is 
absent 
1 = liver disease is 
present 
Independent variables 
PVD Portal vein diameter Interval Cm 
MPVPG Modified portal vein pressure 
gradient = 
PVPG x RPVD x PVR4 
  
HVPG Doppler-derived hepatic vein 
pressure gradient  
     
SVPG Doppler-derived splenic vein 
pressure gradient  
  
PVPG Doppler-derived portal vein 
pressure gradient 
  
HVW Doppler measures of hepatic vein 
waveform 
Ordinal   1 = monophasic 
(continuous flow due 
to increased liver 
resistance or cardiac 
overload) 
2 = biphasic (some 
resistance to flow) 
3 = triphasic (normal) 
ECHO-
GRADE 
Sonographic measures echogenicity  Ordinal   0 = normal (not 
echogenic) 
1 = grainy liver 
(vessels and 
diaphragm seen) 
2 = fatty liver (vessels 
not seen, diaphragm 
seen) 
3 = fatty liver (vessels 
and diaphragm not 
seen) 
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The first group of independent variables included morphometric (changes is size, 
shape, or characteristics) measures of the hepatic venous system made at the interval 
level, specifically the portal vein diameter (PVD). The mean PVD should be about 1.1 
cm (Wiersema, Chak, Kopecky, & Wiersema, 1995). The second group of independent 
variables included physiological measurements of the venous system made at the interval 
level, specifically the Doppler-derived pressure gradients for the hepatic vein (HVPG) 
and the splenic vein (SVPG) in mmHg. The third group of independent variables 
included the results of diagnostic tests, specifically the Doppler measures of hepatic vein 
waveform (HVW), indicated by spectral analysis, measured on an ordinal scale from 1 to 
3, and the sonographic measures of echogenicity (ECHOGRADE), measured on an 
ordinal scale from 0 to 4. 
The modified portal vein pressure gradient (MPVPG), when combined the 
physiological and the morphometric measures into one composite variable, was assumed 
proportional to the blood flow through the portal vein. Proportionality of these combined 
measures is important because the portal vein blood flow profile is closely related to liver 
disease status. MPVPG was based on Poiseuille’s law, which states that the volume of 
fluid passing per unit time through a tube is directly proportional to the pressure gradient 
multiplied by the fourth power of the radius of the tube (Daugherty & Franzini, 2007). A 
more exact method of computing the blood flow through the portal vein is derived by 
calibrating using Poiseuille’s model: 
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where V = the volume of blood (m
3
), t = the time (sec), dV/dt = the flow rate of the blood 
(m
3
/sec), R = the radius of the vein (m), η = the dynamic fluid viscosity of the blood 
(Pascal.sec), ΔP = the pressure gradient (Pascals), and L = the length of the vein (m). All 
the parameters needed to calibrate the model were not available for the purposes of this 
study but are constant within each individual subject.  
Covariates. Demographic profiles of the patients were recorded in the data set in 
terms of their gender and ethnicity. The BMI of each patient was also recorded. Gender 
could influence the relationship between the dependent and independent variables. The 
liver is a sexually dimorphic organ, exhibiting major physiological and biochemical 
differences between men and women (Colby, 1980). The statistical analysis was stratified 
to take into account possible differences between men and women. The category of 
gender was represented in the data set by dummy binary variables coded with 1 = male 
and 2 = female. Ethnicity was recorded to ensure that the dataset adequately reflected the 
general population but is a control variable, not an independent variable (see Table 3).  
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Table 3 
 
Covariates 
Variable Definition Level Measurement 
AGE Age of participant Nominal Only those 18-75 were included 
in dataset 
BMI Body mass index Nominal Only those with BMI < 35 were 
included in dataset 
HISPANIC Caucasian or non-Caucasian 
Hispanic ethnicity 
Nominal   0 = not Hispanic 
1 = Hispanic 
BLACK African American ethnicity  Nominal 0 = not African American 
1 = African American 
WHITE Caucasian ethnicity Nominal 0 = not Caucasian 
1 = Caucasian 
 
 
Analysis 
This study compared the sensitivity and specificity of the independent variables 
with respect to predicting the dependent variable. Specifically, the portal, hepatic, and 
splenic vein pressure gradients, HVW analysis, liver echogenicity, and portal vein 
diameter from the data set were analyzed. The exact method of data collection appears in 
Appendix A. 
Logistic Regression 
 Logistic regression analysis conducted with SPSS Version 17 was used to 
construct predictive models defined by the following generalized equation: 
log p/ (1-p) = β 0 + β 1X1 + β 2X2 + ..... + βkXk 
where log π/(1-π) is the logit (log odds) of an outcome defined by the coding of the 
dependent variable, p = the probability of an outcome defined by the coding of the 
dependent variable, β 0 is a constant or baseline value, and β 1, β 2 . . . βk are the logistic 
regression (β) coefficients for k independent or predictor (X) variables (Hosmer & 
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Lemeshow, 2000). A logistic regression model is specified properly according to the 
measurement level of the dependent variables. In a binary logistic regression model, the 
dependent variable is dichotomous, representing two possible categories, coded in binary 
form with 0 and 1, where 0 = a reference category (e.g., disease is absent) and 1 = an 
observed outcome (e.g., disease is present). Binary logistic regression was appropriate for 
the study using DISEASE (see Table 2) as the dependent variable.  
Statistical Assumptions 
Logistic regression is much less restrictive than linear regression. Unlike linear 
regression, the variables do not have to be normally distributed, linearity between the 
dependent and independent variables is not assumed, and the variance in the dependent 
variable does not have to be equal across all the independent variables (Hosmer & 
Lemeshow, 2000). Logistic regression does, however, assume that excessive 
multicollinearity is not present (i.e., the independent variables must not be too highly 
correlated with each other). If excessive multicollinearity occurs, then the logistic 
regression coefficients and the odds ratios are biased and the overall model becomes 
difficult, if not impossible, to interpret. The computed modified portal vein pressure 
gradient incorporated both the portal vein diameter and the portal vein pressure gradients. 
This combination suggested that there may be at least a moderate degree of 
multicollinearity. For this reason, I used only the modified portal vein pressure gradient 
in the final model. In this study, logistic regression determined whether chronic liver 
disease can or cannot be determined, noninvasively, by any or all of the independent 
variables including the PVD, HVPG, PVPG, MPVPG, SVPG, HVW, or ECHOGRADE.  
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To determine the probability of liver disease based on the independent variables 
(sonographic measures), ROCs was employed. ROCs were generated on only the specific 
independent variables that showed a statistically significant correlation between the 
independent variable and liver disease. ROCs are an efficient way to display the 
relationship between sensitivity and specificity for tests that have continuous outcomes. 
The ROC is a plot of the sensitivity (true positives) relative to the false positive rate 
(Dawson & Trapp, 2004). The closer the proximity of the ROC to the upper left-hand 
corner of the graph, the more accurate the ROC is. In this study, the ROC was be used to 
determine the true positives to the false negatives only on the specific independent 
variables that showed statistical significance by the multiple regression analysis to predict 
liver disease.  
Overall, data analysis sought to answer the following research question: 
Will the hepatic venous pressure gradient (HVPG), the hepatic venous waveform 
(HVW), portal vein diameter (PVD),the portal vein pressure gradient (PVPG), the 
modified portal vein pressure gradient (MPVPG), the splenic vein pressure gradient 
(SVPG), and the echograde (ECHOGRADE) predict the presence or absence of liver 
disease after controlling for age, ethnicity, and BMI, and after stratification by gender?  
 Null hypothesis: The hepatic venous pressure gradient (HVPG), the hepatic 
venous waveform (HVW), portal vein diameter (PVD), the portal vein 
pressure gradient (PVPG), the modified portal vein pressure gradient 
(MPVPG), the splenic vein pressure gradient (SVPG), or the echograde 
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(ECHOGRADE) will not predict the presence or absence of liver disease after 
controlling for age, ethnicity, and BMI, and after stratification by gender. 
 Alternate hypothesis: One or more of the following, including hepatic venous 
pressure gradient (HVPG), the hepatic venous waveform (HVW), portal vein 
diameter (PVD), the portal vein pressure gradient (PVPG), the modified portal 
vein pressure gradient (MPVPG), the splenic vein pressure gradient (SVPG), 
or the echograde (ECHOGRADE) will predict the presence or absence of liver 
disease after controlling for age, ethnicity, and BMI, and after stratification by 
gender.  
One aspect of the study that ensured internal validity was the characterization of 
the dependent and independent variables. Those patients with known hepatitis, liver 
fibrosis, cirrhosis, or esophageal varices had their diagnosis validated by laboratory 
results contained in the patients’ electronic medical records to ensure the patients 
belonged in the respective group. This information was assumed to be accurate in the 
data set.  
Protection of Patient’s Rights 
Informed consent was not required for this study because the study involved a 
retrospective secondary data analysis of a data set with no patient identifiers. In the 
original data collection, a description of the protection of participants’ rights was made 
available to all patients at the time of registration for their abdominal sonogram 
appointment. This protocol adhered to the mandates of the Health Insurance Portability 
and Accountability Act of 1996. This act protects the privacy of health information that 
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could identify the respective patient and is strictly followed by hospitals to protect patient 
rights (U.S. Department of Health and Human Services, n.d.). The participants in the data 
set included patients referred for abdominal sonograms. Hospital internal review board 
approval was properly obtained for the original data collection. The data set did not 
include any identifying patient information such as the medical record number. All data 
was recorded in numerical order only (i.e., 0001, 0002, 0003). Paper copies of the 
recorded data will be maintained by me in a secure file until 5 years after study 
completion. The database will be maintained on an external hard drive purchased 
exclusively for the study and maintained solely by the researcher. The database is 
password-protected to prevent unauthorized access. I obtained Walden institutional 
review board approval to conduct the research. The approval number was 08-08-11-
0075423. 
Summary 
 The ability to noninvasively detect liver disease is of great importance in selection 
of treatment strategies, as well as in the prediction of overall prognosis. The gold 
standard for assessing liver disease, the liver biopsy, is an invasive procedure that carries 
risks. Despite the limitations of liver biopsy and in the absence of better alternatives, it 
remains the gold standard for assessing the severity of liver inflammation and fibrosis. 
Noninvasive tests will predict the chronicity of liver disease and eliminate reliance on 
liver biopsy alone to allow patients to receive more timely diagnosis and treatment before 
irreversible damage occurs. This research sought to predict, through a novel noninvasive 
Doppler method, the presence or absence of chronic liver disease. The chosen statistical 
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analysis included both multiple logistic regression and ROC curves to analyze the data in 
the preexisting dataset. Chapter 4 describes the results of the statistical analysis and 
clinical significance of the findings.   
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Chapter 4: Results 
This chapter presents the results of the analysis of the relationship between the 
pressure gradient in the portal vein, splenic vein, or hepatic vein, and increased liver 
echogenicity, hepatic venous waveform, or portal vein diameter and diagnosis of liver 
disease after controlling for gender, ethnicity, and BMI. The demographics of the 
patients, and their morphometric, physiological, and diagnostic measures are statistically 
described, based on a preexisting data set. I used binary logistic regression to determine 
whether an increase in the portal vein diameter (PVD) associated with an elevated 
modified pressure gradient in the portal vein (MPVPG), together with changes in the 
pressure gradients in the splenic vein (SVPG) and hepatic vein (HVPG), higher 
echogenicity (ECHOGRADE), and changes in the hepatic venous waveform (HVW) 
phases were statistically significant predictors of the likelihood of liver disease. I 
computed sensitivities, specificities, and ROC curves to compare the probabilities at 
which MPVPG, ECHOGRADE, and HVW correctly identified the presence of liver 
disease in male patients and female patients. This chapter presents the findings in five 
sections, including screening, descriptive statistics, collinearity, binary logistic regression 
analysis, and sensitivity and specificity. 
Screening 
 I screened the variables for 545 cases recorded between March 2010 and 
December 2010 in a database at one medical center in the western United States. I 
identified numerous missing values, originally entered as a blank or a zero (see Table 4). 
After exclusion of cases with missing values, the total number of cases was 522. The 
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database included a capacity to classify three mutually exclusive categories of Hispanic 
patients (i.e., Hispanic White, Hispanic Black, and Hispanic American Indian); however, 
no patients were recorded in these categories. All Hispanic patients were therefore 
grouped into one category. 
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Table 4 
 
Variables and Missing Values 
Variable Definition Measures Missing 
GENDER Gender 0 = female 
1 = male 
0 
BMI Body mass index kg/m
2
 4 
WHITE White race (not 
Hispanic) 
0 = no 
1 = yes 
0 
BLACK Black race (not 
Hispanic) 
0 = no 
1 = yes 
0 
HISPANIC Hispanic race 0 = no 
1 = yes 
0 
OTHER Asian or 
American Indian  
0 = no 
1 = yes 
0 
DISEASE Presence of liver 
disease 
0 = liver disease absent 
1 = liver disease present 
0 
PVD Portal vein 
diameter 
mm 5 
PVPG Portal vein 
pressure gradient 
mmHg 14 
MPVPG Modified portal 
vein pressure 
gradient   
mmHg mm
4
 19 
HVPG Doppler-derived 
hepatic vein 
pressure gradient  
mmHg 3 
SVPG Doppler-derived 
splenic vein 
pressure gradient  
mmHg 27 
HVW Doppler measures 
of hepatic vein 
waveform 
1 = monophasic (continuous flow 
due to increased liver resistance 
or cardiac overload) 
2 = biphasic (some resistance to 
flow) 
3 = triphasic (normal) 
4 
ECHO-
GRADE 
Sonographic 
measures of 
echogenicity  
0 = normal (not echogenic) 
1 = grainy liver (vessels and 
diaphragm seen) 
2 = fatty liver (vessels not seen, 
diaphragm seen) 
3 = fatty liver (vessels and 
diaphragm not seen) 
4 
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Descriptive Statistics 
Demographics 
 The demographic profiles of the patients are summarized in Table 5 and Table 6. 
Ethnicity defines a group of people who share a common heritage, language, culture, 
religion, and/or ideology; however, the database did not classify patients according to 
ethnicity, as assumed by the null hypothesis. The categories included in the variable 
RACE were WHITE (not Hispanic); BLACK (not Hispanic); HISPANIC, or OTHER 
(Asian or North American Indian; see Table 5). 
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Table 5 
 
Frequency Distributions of GENDER, BMI, RACE, DISEASE, HVW, and ECHOGRADE 
    Female Male     
Variable Value/code f % f % N % 
GENDER   251 48.1% 271 51.9% 522 100.0% 
BMI 
 
< 25 kg/m
2
 89 17.0% 72 13.8% 161 30.8% 
25-35 kg/m
2
 140 26.8% 164 31.4% 304 58.2% 
> 35 kg/m
2
 22 4.2% 35 6.7% 57 10.9% 
RACE WHITE (not Hispanic) 68 13.0% 84 16.1% 152 29.1% 
 BLACK (not 
Hispanic) 
34 6.5% 36 6.9% 70 13.4% 
 HISPANIC  104 19.9% 112 21.5% 216 41.4% 
 OTHER 45 8.6% 39 7.5% 84 16.1% 
DISEASE Absent 96 18.4% 100 19.2% 196 37.5% 
Present 155 29.7% 171 32.8% 326 62.5% 
HVW 1 = monophasic  35 6.7% 42 8.3% 78 15.0% 
2 = biphasic  77 14.8% 87 16.8% 164 31.6% 
3 = triphasic (normal) 137 26.4% 140 27.0% 277 53.4% 
ECHO 
GRADE 
0 = normal  21 4.0% 17 3.3% 38 7.3% 
1 = grainy liver  80 15.4% 66 12.7% 146 28.0% 
2 = fatty liver  101 19.4% 125 24.0% 226 43.4% 
3 = fatty liver  49 9.4% 62 11.9% 111 21.3% 
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 The sample consisted of 522 patients, with an approximately equal number of 
male patients (n = 251, 48.1%) and female patients (n = 271, 51.9%). The dominant race 
was Hispanic (n = 216, 41.4%), followed in order of percentages by White (n = 152, 
29.1%), other races (n = 84, 16.1%), and Black (n = 70, 13.4%). Men and women were 
relatively equally represented within each racial group (see Table 6).  
 
Table 6 
 
Cross-Tabulation of BMI and GENDER 
BMI 
 
GENDER 
 
(kg/m
2
) Measure Female Male Total 
< 25 f 89 72 161 
 
% within 
GENDER 
35.5% 26.6% 30.8% 
% of Total 17.0% 13.8% 30.8% 
25-35 
f 140 164 304 
% within 
GENDER 
55.8% 60.5% 58.2% 
% of Total 26.8% 31.4% 58.2% 
> 35 
f 22 35 57 
% within 
GENDER 
8.8% 12.9% 10.9% 
% of Total 4.2% 6.7% 10.9% 
 
Over half (n = 304, 58.2%) of the patients were classified as overweight to obese (BMI = 
25-35 kg/m
2
). Over one tenth (n = 57, 10.9%) of the patients were excessively 
overweight (BMI > 35 kg/m
2
). The cross-tabulation (see Table 6) indicated that relatively 
similar proportions of male patients and female patients were within each BMI group. 
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Prevalence of Liver Disease 
Among the 326 patients identified with liver disease, 97 (29.8%) were diagnosed 
with hepatitis, 94 (28.8%) with gallbladder disease, 68 (20.9%) with cirrhosis or ascites, 
and 67 (20.6%) with nonalcoholic steatohepatitis (NASH) or nonalcoholic fatty liver 
disease (NAFLD). The prevalence of liver disease in the sample was relatively equally 
distributed between female patients (n = 155, 29.7%) and male patients (n = 171, 32.8%). 
Liver disease was prevalent among all the racial groups in the sample. Cross-tabulations 
revealed the greatest prevalence of liver disease among the Hispanic female patients. Of 
104 Hispanic female patients, 72 (46.5%) had liver disease. Among 112 Hispanic male 
patients, 72 (42.1%) had liver disease (see Table 7). 
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Table 7 
 
Prevalence of Liver Disease, Stratified by GENDER and RACE 
 
RACE Measure 
DISEASE 
 
GENDER 
Disease 
absent 
Disease 
present N 
Female White f 30 38 68 
 
 
% within 
DISEASE 
31.3% 24.5% 27.1% 
 
 
% of total 12.0% 15.1% 27.1% 
 Black f 13 21 34 
 
 
% within 
DISEASE 
13.5% 13.5% 13.5% 
 
 
% of total 5.2% 8.4% 13.5% 
 Hispanic f 32 72 104 
 
 
% within 
DISEASE 
33.3% 46.5% 41.4% 
 
 
% of total 12.7% 28.7% 41.4% 
 Other f 21 24 45 
 
 
% within 
DISEASE 
21.9% 15.5% 17.9% 
   % of total 8.4% 9.6% 17.9% 
Male White f  34 50 84 
 
 
% within 
DISEASE 
34.0% 29.2% 31.0% 
 
 
% of total 12.5% 18.5% 31.0% 
 Black f 13 23 
 
 
 
% within 
DISEASE 
13.0% 13.5% 13.3% 
 
 
% of total 4.8% 8.5% 13.3% 
 Hispanic f 40 72 112 
 
 
% within 
DISEASE 
40.0% 42.1% 41.3% 
 
 
% of total 14.8% 26.6% 41.3% 
 Other f 13 26 39 
 
 
% within 
DISEASE 
13.0% 15.2% 14.4% 
   % of total 4.8% 9.6% 14.4% 
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The true prevalence of a disease is defined as ―the total number of existing cases 
of a given disease at a given time, divided by the population at that time‖ (Kuzma & 
Bohnenblust, 2005, p. 292). The minimum sample size (N) required to evaluate the true 
prevalence of a given disease in a population, with a margin of error of 5%, is computed 
using the formula 
N = Z
2
 [    (1-   ) ] / e 2 
where Z = 1.96;    is a point estimate or a best guess of the prevalence, based on a 
random sample, and e = .05. The point estimate based on my study sample (i.e., the 
patients treated at a medical center in the western United States from March 2010 to 
December 2010) was 326 / 522 = .625 or 62.5%. Substituting    = .625 into the formula 
indicates that the minimum sample size to evaluate the true prevalence of liver disease in 
the population is N = 360, assuming a 5% margin of error. Consequently, a sample size of 
N = 522 appears to be sufficiently large to measure the true prevalence of liver disease 
among the population of all patients treated at the medical center; however, because my 
study sample was not collected at random, the point estimate is biased and the true 
prevalence of liver disease in the population might not be accurately evaluated. 
Morphometric and Physiological Measures 
The PVD measurements were normally distributed, reflected by bell-shaped 
frequency distributions, whereas the frequency distributions for the MPVPGs were 
skewed (see Figure 1). 
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Figure 1. Frequency distributions of PVD and MPVPG. 
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Figure 2 illustrates the differences between the mean PVD measurements of male 
and female patients in the presence and absence of liver disease.
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Figure 2. Mean PVDs, ± 95% CI. 
When liver disease was absent, the mean PVD (mm) in male patients (M = 8.27, 
SD = 1.95) was .24 mm wider than in female patients (M = 8.03, SD = 2.11). However, 
an independent samples t test indicated that this difference was not significant at α = .05 
(t (194) = .812, p = .418). When liver disease was present, I observed sexual dimorphism 
of the portal vein diameter. The mean PVD in male patients (M = 10.15, SD = 3.30) was 
1.3 mm wider than in female patients (M = 8.85, SD = 2.72). An independent samples t 
test assuming equal variances indicated that the difference between the mean PVD in 
male patients and female patients with liver disease was statistically significant at α = .05 
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(t (324) = 3.911, p < .001). Sexual dimorphism of the portal vein had implications for the 
computation of the ratio of the observed PVD to the mean PVD in the absence of liver 
disease (RPVD). The RPVD (PVD/M) was calculated assuming M = 8.27 mm for male 
patients and M = 8.03 mm for female patients.  
Theoretically, it is not essential that the variables in a binary logistic regression 
analysis be normally distributed; however, highly skewed predictor variables might cause 
instability including inaccurate odds ratios and 95% confidence intervals (Hosmer & 
Lemeshow, 2000). A log10 (logt) transformation was therefore used to normalize the 
MPVPG measurements. Normality was indicated by approximately bell-shaped 
frequency distributions (see Figure 3). 
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Figure 3. Frequency distribution of logt MPVPG. 
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The mean logt MPVPGs ± 95% confidence intervals in male and female patients 
with and without liver disease are compared in Figure 4. When liver disease was absent, 
the MPVPG in male patients (logt M = 1.527, SD =.532; antilog M = 33.65) was similar 
to that in female patients (logt M = 1.482, SD = .622; antilog M = 30.33). An independent 
samples t test assuming equal variances indicated that the difference in mean MPVPG 
with respect to gender was not statistically significant at α = .05 (t (194) = .511, p = 
.582). When liver disease was present, the MPVPG in men (logt M = 1.958, SD = .763; 
antilog M = 90.78) was higher than that in women (logt M = 1.711, SD = .675; antilog M 
= 51.40). An independent samples t test assuming equal variances indicated that the 
difference between the logt mean MPVPG in male patients and female patients with liver 
disease was statistically significant at α = .05 (t (324) = 3.079, p = .002).   
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Figure 4. Mean logt MPVPGs ± 95% CIs with respect to DISEASE and GENDER. 
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The skewed HVPG and SVPG measurements were normalized by logarithmic 
transformations. For a graphic representation to compare the logarithmically transformed 
measurements ± 95% confidence intervals (see Figure 5.) 
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Figure 5. Mean HVPGs and SVPGs ± CIs with respect to DISEASE and GENDER. 
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Independent samples t tests assuming equal variances revealed no statistically 
significant differences at α = .05 between the mean logt HVPG in male patients and 
female patients when liver disease was absent (t (189) = .719, p = .473) and when liver 
disease was present (t (314) = 1.797, p = .073). I found a statistically significant 
difference in the mean logt SVPG between male patients and female patients when liver 
disease was absent (t (165) = 2.168, p = .032) but not when liver disease was present (t 
(293) = .859, p = .859). 
Hepatic Vein Waveform 
Cross-tabulation revealed that among 325 patients diagnosed with liver disease, 
the abnormal monophasic and biphasic waveforms (HVW 1 and HVW 2) were observed 
among 175 (53.8%), compared to 67 (34.5%) of the 194 patients who were not diagnosed 
with liver disease (see Table 8). 
 
Table 8 
 
Cross-Tabulation of Prevalence of Liver Disease and HVW Phase 
HWV phase Measure 
DISEASE 
 Disease Disease 
N absent present 
1 (monophasic) f 13 65 78 
 
% 2.5% 12.5% 15.0% 
2 (biphasic) f 54 110 164 
 
% 10.4% 21.2% 31.6% 
3 (triphasic) f 127 150 277 
 
% 24.5% 28.9% 53.4% 
Total 
 
194 325 519 
% 
 
37.4% 62.6% 100.0% 
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Echogenicity 
I found positive echogenic evidence for fatty liver (ECHOGRADE > 1) in over 
three quarters (n = 250, 76.9%) of the 325 patients who were diagnosed with liver 
disease, and in less than half (n = 87, 44.4%) of the 196 patients who did not have liver 
disease (see Table 9). 
 
Table 9 
 
Cross-Tabulation of Prevalence of Liver Disease and ECHOGRADE Score 
ECHOGRADE   
  DISEASE 
N Measure 
Disease 
absent 
Disease 
present 
0 (normal)  f 29 9 38 
 % 5.6% 1.7% 7.3% 
1 (grainy liver; vessels and 
diaphragm seen) 
f 80 66 146 
 % 15.4% 12.7% 28.0% 
2 (fatty liver; vessels not seen; 
diaphragm seen) 
f 62 164 226 
 % 11.9% 31.5% 43.4% 
3 (fatty liver; vessels and 
diaphragm not seen) 
f 25 86 111 
 % 4.8% 16.50% 21.30% 
Total  196 325 521 
%  37.6% 62.4% 100.0% 
 
Collinearity 
Collinearity inflates the variances, resulting in lack of statistical significance for 
the predictor variables, and the wrong signs and magnitudes for the regression 
coefficients (Homer & Lemeshow, 2000). Consequently, I explored the intercorrelations 
using a matrix of Cramer’s V coefficients between the nominal and/or ordinal level 
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variables (see Table 10) and Spearman’s rank correlation coefficients between the ordinal 
and/or interval level variables (see Table 11).  
 
Table 10 
 
Correlations (Cramer’s V Coefficients) Between DISEASE, BMI, RACE, HVW, and 
ECHOGRADE 
Gender Variable DISEASE BMI RACE HVW 
Female BMI .128       
  RACE .138 .211*     
  HVW .155* .159* .103   
  ECHOGRADE .371* .126 .082 .107 
Male BMI .100       
  RACE .053 .046     
  HVW .271* .073 .115   
  ECHOGRADE .333* .069 .106 .156* 
 
Note. * Significant correlation at p < .05. 
 
 
  
 
8
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Table 11 
 
Correlations (Spearman’s Rank Coefficients) Between BMI, MPVPG, SVPG, HVPG, ECHOGRADE, HVW, and PVD 
GENDER  VARIABLE BMI MPVPG  SVPG HVPG ECHOGRADE  HVW 
Female MPVPG  .085      
 SVPG -.069 .163*     
 HVPG .115 .051 -.057    
 ECHOGRADE .070 -.076 -.036 -.034   
 HVW .200* -.152* -.121 .038 -.111  
 PVD .083 .945* .092 .040 -.057 -.161* 
Male MPVPG  -.208*      
 SVPG -.053 .179*     
 HVPG -.023 .052 .041    
 ECHOGRADE .014 .018 -.042 -.033   
 HVW .070 .132* -.127* -.029 -.158*  
 PVD -.213* .952* .141* .051 .061 -.142* 
 
Note. * Significant correlation at p < .05. 
89 
 
 
 
The dependent variable DISEASE was positively correlated with HVW and 
ECHOGRADE at p < .05 in both male patients and female patients, reflecting the 
significance of Doppler measures of HVW and sonographic measures of echogenicity for 
the diagnosis of liver disease (see Table 11). I found some statistically significant 
coefficients (Cramer's V = .159 to .211) between BMI and RACE (see Table 11) and 
between the MPVPG, SVGP, ECHOGRADE, and HVW (Spearman’s ρ = .132 to .163), 
reflecting weak correlations between the predictor variables (see Table 12). The MPVPG 
is a mathematical function of the PVD; consequently, the MPVPG and the PVD were 
strongly correlated (Spearman’s ρ = .945, p < .001 for women and Spearman’s ρ = .952, 
p < .001 for men).   
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Table 12 
 
Logistic Regression Model I to Predict the Presence of Liver Disease Among Female Patients (N = 251, Including BMI > 35) 
 
       95% CI for OR 
Gender                       Predictor B       SE Wald df             p           OR Lower Upper 
Female  WHITE .091 .517 .031 1 .860 1.095 .398 3.017 
BLACK .145 .584 .062 1 .803 1.156 .368 3.629 
HISPANIC .972 .497 3.830 1 .050* 2.643 .999 6.998 
LogtMPVPG .751 .282 7.111 1 .008* 2.118 1.220 3.678 
LogtSVPG .605 .890 .462 1 .497 1.831 .320 10.488 
LogtHVPG .697 .624 1.245 1 .264 2.007 .590 6.821 
ECHOGRADE   35.372 3 < .001*    
ECHOGRADE(1) .759 .571 1.766 1 .184 2.137 .697 6.550 
  ECHOGRADE(2) 2.496 .596 17.533 1 < .001* 12.131 3.772 39.016 
ECHOGRADE(3) 3.158 .740 18.219 1 < .001* 23.535 5.519 100.366 
HVW   5.975 2 .051    
HVW(1) 1.190 .636 3.502 1 .061 3.287 .945 11.430 
HVW(2) .738 .391 3.567 1 .059 2.091 .973 4.495 
Constant -2.264 1.178 3.696 1 .055 .104   
 
Note. B = regression coefficient. SE = standard error. Wald = Wald's χ2. OR = odds ratio. CI = confidence interval. * Significant 
at p < .05. 
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Binary Logistic Regression Models  
 Although I identified statistically significant correlations between MPVPG, 
HVPG, ECHOGRADE, SVPG, and HVW (see Table 12), I found no evidence for strong 
collinearity, indicated by correlation coefficients > .8. Consequently, it was justified to 
include these five measures as predictors of liver disease in the logistic regression. 
Because the collinearity between the PVD and the MPVPG could bias the statistical 
inferences, the PVD was not included as an independent variable alongside the MPVPG. 
It is a common practice to combine the variables responsible for collinearity into a single 
variable (Homer & Lemeshow, 2000). 
I constructed four binary logistic regression models using SPSS to predict the log 
odds of liver disease (1 = disease present or 0 = disease absent) in 522 patients, stratified 
by gender (n = 251 female patients and n = 271 male patients). MODEL I was 
constructed for all female patients and MODEL II for all male patients. Model III 
excluded 22 obese female patients with BMI > 35. Model IV excluded 35 obese male 
patients with BMI > 35.   
I interpreted the odds ratios (ORs) and their 95% confidence intervals (CIs) for 
each predictor variable. The ORs were computed for each category of RACE, 
ECHOGRADE, and HVW, relative to their reference categories. I stipulated 0 (no) as the 
reference category for RACE, represented by the dummy variables, WHITE, BLACK, 
and HISPANIC, where 1 = yes or 0 = no. I entered ECHOGRADE as one ordinal 
variable, containing four levels (0, 1, 2, and 3) where 0 (normal) was the stipulated 
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reference category. I entered HVW as one ordinal variable, containing three levels (1, 2, 
and 3) where 3 (triphasic or normal waveform) was the stipulated last reference category.    
MODEL I. Females, Including BMI > 35 
I constructed the first binary logistic regression model to predict the likelihood of 
the presence of liver disease among 251 female patients, including those with BMI > 35 
(see Table 13.) The omnibus tests of the model coefficients indicated that the model was 
statistically significant (χ2 ,11 = 61.704, p < .001). The Nagelkerke R square was .343. 
The null hypothesis was rejected. I found that RACE (HISPANIC), MPVPG, and 
ECHOGRADE were statistically significant predictors of the likelihood of liver disease. 
The edited SPSS output is presented in Table 13 (where B is the regression coefficient, 
SE is the standard error, Wald is the Wald's χ2 statistic, OR is the odds ratio, and CI is the 
confidence interval). 
The race variables of BLACK and WHITE, together with the physiological 
measurements of HVPG, SVPG, and HVW, were not significant predictors of liver 
disease in the female patients, indicated by p ≥ .05 for Wald’s χ2. The race variable of 
HISPANIC was, however, a marginally significant predictor (χ2, 1 = 3.830, p = .05). The 
OR indicated that the likelihood of a Hispanic woman having liver disease would be, on 
average, 2.643 times greater than that of a non-Hispanic woman. The 95% CI indicated 
that the mean OR in the population was .999 to 6.998 in 95% of cases. This CI is 
consistent with the cross-tabulation revealing the highest prevalence of liver disease 
among Hispanic female patients (see Table 6). Logt MPVPG was a significant predictor 
of liver disease (χ2, 1 = 7.111, p = .008). The likelihood of liver disease was predicted to 
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be 2.118 times greater for every logarithmic (log10) unit increase in MPVPG (95% CI = 
1.220, 3.678). ECHOGRADE was a significant predictor of liver disease (χ2,3 = 35.372, 
p < .001) in female patients. If ECHOGRADE = 1, then the likelihood of a female having 
liver disease was the same as that of a patient whose ECHOGRADE = 0 (i.e., normal) 
because the OR was not significantly different from 1.0. If ECHOGRADE = 2, then the 
likelihood of a woman having liver disease would be approximately 12 times greater than 
that of a patient whose ECHOGRADE was 0 (95% CI = 3.772, 39.016). If 
ECHOGRADE = 3, then the likelihood of a female patient having liver disease would be 
more than 23 times greater (95% CI = 5.519, 100.366). Sonographic measures of 
echogenicity (ECHOGRADE = 2 and 3) provided the highest ORs (12.131 and 25.535, 
respectively) with respect to diagnosing the presence of liver disease in women. HVW 
was not a significant predictor of liver disease at α = .05. 
Model II. Males, Including BMI > 35 
I constructed the second binary logistic regression model to predict the likelihood 
of the presence of liver disease among 271 male patients including those with BMI > 35. 
The edited SPSS output is presented in Table 13. The omnibus tests of the model 
coefficients indicated that the model was statistically significant (χ2 ,11 = 64.161, p < 
.001). The Nagelkerke R square was .329. The null hypothesis was rejected. I found that 
MPVPG, SVPG, ECHOGRADE, and HVW were statistically significant predictors of 
the likelihood of liver disease. 
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Table 13 
 
Logistic Regression Model II to Predict the Presence of Liver Disease Among Male Patients (N = 271, Including BMI > 35) 
       95% CI for OR 
Gender                       Predictor           B             SE Wald df         p       OR Lower Upper 
Male  WHITE 
.257 .498 .266 1 .606 1.293 .487 3.432 
BLACK 
.198 .581 .116 1 .733 1.219 .391 3.803 
HISPANIC 
.338 .474 .510 1 .475 1.403 .554 3.551 
LogtMPVPG 
1.119 .265 17.869 1 < .001* 3.063 1.823 5.146 
LogtSVPG 
-1.999 .767 6.787 1 .009* .135 .030 .610 
LogtHVPG 
-.877 .635 1.909 1 .167 .416 .120 1.444 
ECHOGRADE 
  16.972 3 < .001*    
ECHOGRADE(1) 
1.886 .778 5.885 1 .015* 6.594 1.437 30.268 
ECHOGRADE(2) 
2.779 .754 13.581 1 < .001* 16.105 3.673 70.610 
ECHOGRADE(3) 
2.709 .806 11.288 1 .001* 15.020 3.092 72.961 
HVW 
  12.064 2 .002*    
HVW(1) 
1.659 .559 8.810 1 .003* 5.257 1.757 15.726 
HVW(2) 
.849 .360 5.552 1 .018* 2.338 1.154 4.740 
Constant 
-6.506 1.295 25.247 1 .000* .001   
Note. B = regression coefficient. SE = standard error. Wald = Wald's χ2. OR = odds ratio. CI = confidence interval. * Significant 
at p < .05. 
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Among the male patients , the race variables of BLACK, WHITE, and 
HISPANIC and the measurement of HVPG were not statistically significant predictors of 
liver disease, indicated by p > .05 for the Wald’s χ2statistics. Logt MPVPG was, 
however, a significant predictor of liver disease (χ2, 1 = 17.869, p < .001). The likelihood 
of liver disease would be, on average, about 3 times greater for every one log10 increase 
in MPVPG (95% CI = 1.823, 5.146). In contrast, the odds changed by .135 (95% CI = 
.030, .160) for every 1 unit change in logt SVPG. The OR of less than 1 implied that the 
likelihood of liver disease was less when the SVPG increased, consistent with the results 
presented earlier in this chapter (see Figure 5), indicating that the mean SVGP was 
highest in male patients without liver disease. 
For the male patients, including those with BMI > 35, ECHOGRADE was a 
highly significant predictor of liver disease (χ2, 3 = 972, p < .001). If ECHOGRADE = 1, 
then the likelihood of a male patient having liver disease was about 6.6 times greater 
(95% CI = 1.437, 30.268) than a patient whose ECHOGRADE was 0 (i.e., normal). If 
ECHOGRADE = 2, then the likelihood of the presence of liver disease would be, on 
average, approximately 16 times greater than that of a patient whose ECHOGRADE was 
0 (95% CI = 3.673, 70.610). If ECHOGRADE = 3, then the likelihood of a male patient 
having liver disease would be, on average, approximately 15 times greater (95% CI = 
3.092, 72.961).  
The HVW was a significant predictor of liver disease in male patients, including 
those with BMI < 35 (χ2, 2 = 12.064, p = .002). If HVW = 1 (i.e., monophasic), then the 
likelihood of liver disease was about 5.3 times greater (95% CI = 1.757, 15.726) than a 
96 
 
 
patient whose HVW = 3 (i.e., triphasic or normal). If HVW = 2 (i.e., biphasic), then the 
likelihood of a man having liver disease would be, on average, approximately 2.3 times 
greater (95% CI = 1.154, 4.470) than that of a patient whose HVW was triphasic.  
Sonographic measures of echogenicity (ECHOGRADE = 1, 2, and 3) provided 
the highest ORs (6.954, 16.105, and 15.020, respectively) to predict the presence of liver 
disease in men. The OR estimates for HVW (1 and 2) were less than those for 
ECHOGRADE (OR = 5.257 and 2.338, respectively). The logt MPVG, based on a 
different scale of measurement to ECHOGRADE and HVW, provided the lowest 
likelihood for predicting liver disease in men (OR = 3.063). 
Model III. Females, Excluding BMI > 35 
I constructed the third binary logistic regression model to predict the likelihood of 
the presence of liver disease among 195 female patients who had a BMI of less than 35. 
The edited SPSS output is presented in Table 14. The omnibus tests of the model 
coefficients indicated that the model was statistically significant (χ2 ,11 = 69.433, p < 
.001). The Nagelkerke R square was .413. The null hypothesis was rejected. I found that 
RACE (HISPANIC), MPVPG, HVW, and ECHOGRADE were statistically significant 
predictors of the likelihood of liver disease. Among the female patients with BMI < 35, 
the race variables of BLACK and WHITE and the physiological measurements of HVPG 
and SVPG were not significant predictors of liver disease, indicated by p > .05 for 
Wald’s χ2. The race variable of HISPANIC was, however,  a significant predictor (χ2, 1 = 
4.161, p = .041). The OR indicated that the likelihood of a Hispanic woman having liver 
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disease would be, on average, almost three times greater than that of a female patient who 
was not Hispanic (95% CI = 1.044, 8.530). 
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Table 14 
 
Logistic Regression Model III to Predict the Presence of Liver Disease Among Female Patients (N = 195, with BMI < 35) 
Gender                         Predictor         B         SE        Wald df        p           OR 
95% CI for OR 
      Lower     Upper 
Female  WHITE .328 .559 .345 1 .557 1.389 .464 4.155 
BLACK .448 .654 .468 1 .494 1.565 .434 5.639 
HISPANIC 1.093 .536 4.161 1 .041* 2.984 1.044 8.530 
Logt MPVPG .822 .311 6.973 1 .008* 2.274 1.236 4.185 
Logt SVPG .467 .949 .242 1 .623 1.595 .248 10.237 
Logt HVPG .969 .682 2.020 1 .155 2.635 .693 10.024 
ECHOGRADE   40.236 3 .000*    
ECHOGRADE(1) .548 .577 .903 1 .342 1.730 .558 5.359 
ECHOGRADE(2) 2.847 .626 20.699 1 .000* 17.240 5.056 58.781 
ECHOGRADE(3) 3.558 .850 17.534 1 .000* 35.091 6.637 185.543 
HVW   5.860 2 .053    
HVW(1) 1.106 .687 2.595 1 .107 3.022 .787 11.606 
HVW(2) .912 .436 4.374 1 .046* 2.489 1.059 5.851 
Constant -2.549 1.264 4.065 1 .044* .078   
 
Note. B = regression coefficient. SE = standard error. Wald = Wald's χ2. OR = odds ratio. CI = confidence interval. * Significant 
at p < .05. 
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I found that MPVPG was a significant predictor of liver disease in female patients 
with a BMI < 35 (χ2, 1 = 6.973, p = .008). The likelihood of liver disease would be about 
2.3 times greater for every 1-unit increase in logt MPVPG (95% CI = 1.236, 4.185).  
ECHOGRADE was also a highly significant predictor of liver disease (χ2, 3 = 
40.236, p < .001). If ECHOGRADE = 1, then the likelihood of a female patient having 
liver disease was the same as that of a patient whose ECHOGRADE = 0 (i.e., normal) 
because the OR was not significantly different from 1.0. If ECHOGRADE = 2, then the 
likelihood of a woman having liver disease would be, on average, approximately 17.2 
times greater than that of a patient whose ECHOGRADE was 0 (95% CI = 5.056, 
58.781). If ECHOGRADE = 3, then the likelihood of a female patient having liver 
disease would be, on average, approximately 35 times greater (95% CI = 6.637, 185.453).  
The HVW was a marginally significant predictor of liver disease in women with a 
BMI < 35 (χ2, 2 = 5.860, p =.053). If HVW = 2, then the likelihood of liver disease was 
about 2.5 times greater (95% CI = 1.059, 5.851) than if HVW = 3 (normal). 
Model IV. Males, Excluding BMI > 35 
I constructed the fourth binary logistic regression model to predict the likelihood 
of the presence of liver disease among 202 male patients who had a BMI < 35. The edited 
SPSS output is presented in Table 15. The omnibus tests of the model coefficients 
indicated that the model was statistically significant (χ2 ,11 = 56.478, p < .001). The 
Nagelkerke R square was .337. The null hypothesis was rejected. I found that MPVPG, 
SVPG, ECHOGRADE, and HVW were statistically significant predictors of the 
likelihood of liver disease.  
  
 
 
1
0
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Table 15 
 
Logistic Regression Model IV to Predict the Presence of Liver Disease Among Male Patients (N = 202, with BMI < 35) 
         95% CI for OR 
Gender  Predictor            B          SE         Wald df         p     OR Lower        Upper 
 Male  WHITE  
BLACK 
.099 
-.437 
.564 
.639 
.031 
.468 
1 
1 
.861 
.494 
1.104 
.646 
.366 
.184 
3.331 
2.261 
HISPANIC -.214 .529 .163 1 .686 .808 .287 2.276 
LogtMPVPG 1.094 .287 14.518 1 < .001* 2.985 1.701 5.239 
LogtSVPG -2.332 .830 7.887 1 .005* .097 .019 .494 
LogtHVPG -.767 .684 1.260 1 .262 .464 .122 1.773 
ECHOGRADE   11.418 3 .010*    
ECHOGRADE(1) 1.762 .818 4.636 1 .031* 5.826 1.171 28.978 
ECHOGRADE(2) 2.448 .791 9.577 1 .002* 11.560 2.453 54.468 
ECHOGRADE(3) 2.510 .850 8.713 1 .003* 12.306 2.324 65.153 
HVW   12.096 2 .002*    
HVW(1) 1.866 .619 9.087 1 .003* 6.462 1.921 21.739 
HVW(2) 
Constant 
.901 
-6.090 
.396 
1.380 
5.172 
19.463 
1 
1 
.023* 
< .001* 
2.463 
.002 
1.133 
 
 
5.356 
 
 
Note. B = regression coefficient. SE = standard error. Wald = Wald's χ2. OR = odds ratio. CI = confidence interval. * Significant 
at p < .05. 
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Among the male patients (see Table 15) with BMI < 35, the race variables of 
BLACK, WHITE, and HISPANIC and the variable HVPG were not significant predictors 
of liver disease, indicated by p > .05 for Wald’s χ2. Logt MPVPG was, however, a 
significant predictor of liver disease (χ2, 1 = 14.518, p < .001). The OR indicated that the 
likelihood of liver disease would be, on average, nearly 3 times greater for every 
logarithmic unit increase in MPVPG (95% CI = 1.701, 5.239). In contrast, the odds 
changed by only .097 (95% CI = .019, .494) for every 1-unit increase in logt SVPG. 
ECHOGRADE was a significant predictor of liver disease (χ2, 3 = 11.418, p = .010) in 
male patients with a BMI < 35. If ECHOGRADE = 1, then the likelihood of a male 
patient having liver disease would be about 5.8 times greater than a patient wiwth 
ECHOGRADE = 0 (95% CI = 1.171, 28.978). If ECHOGRADE = 2, then the likelihood 
of a man having liver disease would be, on average, approximately 11.6 times greater 
(95% CI = 2.453, 54.468). If ECHOGRADE = 3, then the likelihood of a male patient 
having liver disease would be, on average, approximately 12.3 times greater (95% CI = 
2.324, 65.153). HVW was also a significant predictor of liver disease in male patients (χ2, 
2 = 12.096, p = .002). If HVW = 1 (i.e., monophasic), then the likelihood of a male 
patient having liver disease was about 6.5 times greater (95% CI = 1.921, 21.739) than a 
patient whose HVW = 3 (i.e., triphasic). If HVW = 2 (i.e., biphasic), then the likelihood 
of a man having liver disease would be, on average, approximately 2.5 times greater 
(95% CI = 1.133, 5.356) than if the HVW was triphasic. 
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Sonographic measures of echogenicity (ECHOGRADE = 1, 2, and 3) provided 
the highest ORs (OR = 5.826, 11,560, and 12.306, respectively) to predict the presence of 
liver disease in men with a BMI < 35. The HVW (1 and 2) also provided relatively high 
ORs for predicting liver disease in men (OR = 6.462 and 2.463, respectively) relative to 
those with a triphasic waveform. Logt MPVG, using a different scale of measurement to 
ECHOGRADE and HVW, provided a relatively low OR (2.985) for predicting the 
presence of liver disease.  
Sensitivity and Specificity 
Sensitivity is the conditional probability that the test will be positive if the disease 
is present. Specificity is the conditional probability that the test will be negative if the 
disease is absent. Sensitivity and specificity cannot exceed 100%, and neither can their 
CIs. The lower and upper limits of the 95% CIs in this study were calculated using the 
efficient-score method, corrected for continuity, as described by Newcombe (1998). I 
used an online calculator to compute the sensitivity and specificity values (Lowry, n.d.). 
 I estimated and compared the sensitivities and specificities with respect to (a) 
MPVPG; (b) ECHOGRADE; (c) HVW; and (d) a combination of MPVGP, 
ECHOGRADE, and HVW using the predictions made by the four logistic regression 
models. The predictions of DISEASE were obtained using the save predicted group 
membership option in SPSS, where 0 = disease absent and 1 = disease present.  
I cross-classified the frequencies of 251 female patients (see Table 16) and 271 
male patients (see Table 17) according to whether liver disease was present or absent as 
declared by Fibrotest (FT)® and/or Alanine aminotransferase (ALT) markers (in the 
103 
 
 
columns) and according to whether MPVPG liver disease was present or absent at eight 
specified MPVPG cutoff levels (in the rows). The midpoint sensitivities, specificities, and 
95% CIs were calculated using the methods described by Kuzma and Bohnenblust 
(2005). The specificity varied between male patients and female patients. In female 
patients, the specificity was 100% at MPVPG ≥ 1000, declining to 93.8% at MPVPG ≥ 
250, 77.0% at MPVPG ≥ 100, and 21.8% at MPVPG ≥ 10 (see Table 15). In male 
patients, the specificity declined from 99.0% at MPVPG ≥ 1000 to 81% at MPVPG ≥ 
250, 81.0% at MPVPG ≥ 100, and 15.0% at MPVPG ≥ 10 (see Table 16). 
 
Table 16 
 
Sensitivity and Specificity at Eight Cutoff Levels of MPVPG Among Female Patients (N = 
251) 
 DISEASE   95% CI 
MPVPG 
cutoff level 
Disease 
absent 
Disease 
present 
Conditional 
probability 
Mid-
point Lower  Upper 
≥10 75 134 Sensitivity .864 .798 .912 
< 10 21 21 Specificity .218 .143 .317 
≥25 56 105 Sensitivity .677 .596 .749 
< 25 40 50 Specificity .417 .318 .522 
≥ 50 39 76 Sensitivity .490 .409 .571 
< 50 57 79 Specificity .593 .488 .691 
≥ 75 30 62 Sensitivity .400 .323 .481 
< 75 66 93 Specificity .687 .583 .776 
≥ 100 22 53 Sensitivity .341 .268 .422 
< 100 74 102 Specificity .770 .671 .847 
≥ 250 6 26 Sensitivity .167 .114 .238 
< 250 91 129 Specificity .938 .864 .974 
≥ 500 1 13 Sensitivity .084 .047 .142 
< 500 95 142 Specificity .989 .935 .999 
≥ 1000 0 4 Sensitivity .025 .008 .069 
< 1000 96 151 Specificity 1.000 .952 1.000 
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Table 17 
 
Sensitivity and Specificity at Eight Cutoff Levels of MPVPG Among Male Patients (N = 
271) 
 DISEASE   95% CI 
MPVPG 
cutoff level 
Disease 
absent 
Disease 
present 
Conditional 
probability 
Mid- 
point Lower Upper 
≥ 10  85 156 Sensitivity .912 .856 .948 
< 10  15 15 Specificity .150 .089 .238 
≥ 25  58 130 Sensitivity .760 .687 .821 
< 25  42 41 Specificity .420 .323 .523 
≥ 50  36 110 Sensitivity .880 .806 .929 
< 50  64 61 Specificity .294 .179 .440 
≥ 75  30 124 Sensitivity .617 .611 .720 
< 75  70 77 Specificity .700 .598 .785 
≥ 100  19 84 Sensitivity .491 .414 .568 
< 100  81 87 Specificity .810 .717 .878 
≥ 250  4 46 Sensitivity .269 .206 .343 
< 250  96 125 Specificity .960 .894 .987 
≥ 500  3 31 Sensitivity .181 .128 .249 
< 500  97 140 Specificity .970 .908 .992 
≥ 1000  1 14 Sensitivity .082 .047 .136 
< 1000  99 157 Specificity .990 .938 .999 
 
A ROC curve (see Figure 6) is a visual representation of the relationship between 
the sensitivity (percentage of true-positive tests) and 1 - specificity (percentage of false-
positive tests) based on the eight cutoff points of MPVPG used in Table 16 and Table 17.   
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Figure 6. ROC curves for eight cutoff levels of MPVPG in male and female patients. 
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The two ROC curves (see Figure 6) revealed that the sensitivity for each cutoff 
level of MPVPG was generally greater among male patients than among female patients. 
Each graph was not a typical rectilinear ROC curve with a distinct inflexion point at the 
top left-hand corner, representing a high proportion of true positives corresponding to a 
low proportion of false positives. The shallow slopes of the ROC curves without distinct 
inflexion points indicated that if any given level of MPVPG assumed to represent a 
positive test for liver disease is lowered, then the sensitivity is increased, and the false-
positive rate is also increased. Consequently, it is difficult to choose an appropriate level 
of MPVPG to represent a true-positive test result. Nevertheless, based on the 
logarithmically transformed MPVPGs in male patients (antilog M = 90.78) and female 
patients (antilog M = 51.40) diagnosed with liver disease, I suggest tentatively that 
positive test results with reasonable sensitivity could be declared if the MPVG is ≥ 50 
mmHg mm
4
. 
The sensitivities for the sonographic measures of echogenicity in male patients 
and female patients, for comparison with those computed for the MPVPGs, are presented 
in Table 18 and Table 19, respectively. The sensitivities remained relatively high (85.3% 
to 96.8%) and the specificities remained relatively low (25.0% to 62.5%) across all three 
levels of ECHOGRADE (1, 2, and 3) relative to ECHOGRADE 0 (normal). For the male 
patients, the sensitivities were consistently higher and the specificities were consistently 
lower than for the female patients. Because there were only three points, I considered it 
inappropriate to construct ROC curves for the ECHOGRADE scores. 
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Table 18 
 
Sensitivity and Specificity for Two Cutoff Levels of ECHOGRADE in Female Patients 
 DISEASE   95% CI 
ECHOGRADE 
cut-off level 
Disease 
absent 
Disease 
present 
Conditional 
probability 
Mid- 
point Lower Upper 
1 (positive) 45 35 Sensitivity .853 .701 .939 
0 (negative) 15 6 Specificity .250 .151 .381 
2 (positive) 27 74 Sensitivity .925 .838 .969 
0 (negative) 15 6 Specificity .357 .219 .520 
3 (positive) 9 40 Sensitivity .869 .730 .945 
0 (negative) 15 6 Specificity .625 .407 .804 
 
Table 19 
 
Sensitivity and Specificity for Two Cutoff Levels of ECHOGRADE in Male Patients 
 DISEASE   95% CI 
ECHOGRADE 
cut-off level 
Disease 
absent 
Disease 
present 
Conditional 
probability 
Mid- 
point Lower Upper 
1 (positive) 35 31 Sensitivity .911 .752 .977 
0 (negative) 14 3 Specificity .286 .170 .435 
2 (positive) 35 90 Sensitivity .968 .902 .991 
0 (negative) 14 3 Specificity .286 .170 .435 
3 (positive) 16 46 Sensitivity .938 .821 .984 
0 (negative) 14 3 Specificity .467 .288 .653 
 
I found that the estimated sensitivities for the two phases of HVW in male 
patients and female patients were lower than those estimated for the ECHOGRADE 
scores (see Table 20 and Table 21, respectively). The sensitivities for the monophasic and 
biphasic waveforms, relative to the triphasic (normal) waveform, were consistently 
higher (34.2% and 44.7%) in male patients than in female patients (25.9% and 29.8%). 
The specificities for the monophasic and biphasic waveforms in male patients (93.0% and 
70.5%) were also consistently higher than in female patients (88.2% and 69.8%). Because 
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there were only two points, I considered it inappropriate to construct ROC curves for the 
HVW phases. 
 
Table 20 
 
Sensitivity and 
Specificity for 
Two Cutoff 
Levels of HVW 
in Male Patients DISEASE   95% CI 
HVW cutoff  
level 
Disease 
absent 
Disease 
present 
Conditional 
probability 
Mid- 
point Lower Upper 
1 (monophasic) 5 38 Sensitivity .342 .256 .439 
3 (triphasic) 67 73 Specificity .930 .838 .974 
2 (biphasic) 28 59 Sensitivity .447 .361 .535 
3 (triphasic) 67 73 Specificity .705 .601 .792 
 
 
 
Table 21 
 
Sensitivity and Specificity for Two Cutoff Levels of HVW in Female Patients 
 DISEASE   95% CI 
HVW cutoff 
level 
Disease 
absent 
Disease 
present 
Conditional 
probability 
Mid- 
point Lower Upper 
1 (monophasic) 8 27 Sensitivity .259 .180 .356 
3 (triphasic) 60 77 Specificity .882 .775 .944 
2 (biphasic) 26 51 Sensitivity .398 .314 .489 
3 (triphasic) 60  77 Specificity .698 .588 .789 
 
 
I found that the estimated sensitivities based on the group memberships (0 = 
disease absent or 1 = disease present) predicted by the four logistic regression models 
(see Table 22) were consistently lower than those estimated for the ECHOGRADE scores 
(see Table 18 and Table 19) but consistently higher than those estimated for the HVW 
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scores (see Table 20 and Table 21). The midpoint sensitivities for the female patients 
using Models I and III (74.3% and 82.0%) were similar to the sensitivities for the male 
patients using Models II and IV (73.5% and 76.6%). The sensitivities appeared to be 
consistently higher within each gender when obese patients with BMI > 35 were 
excluded; however, because the 95% confidence intervals were wide and overlapped, no 
significant differences between the sensitivities at the .05 level could be inferred.  
 
Table 22 
 
Sensitivity and Specificity Using the Predictions of the Logistic Regression Models 
  
DISEASE   95% CI 
Model   
Predicted 
group 
Membership 
Disease 
absent 
Disease 
present 
Conditional 
probability 
Mid- 
point Lower  Upper 
I  1 27 110 Sensitivity .743 .663  .809 
  0 39 38 Specificity .590 .463  .708 
II 1 22 128 Sensitivity .735 .662  .798 
  0 38 46 Specificity .633 .498  .751 
III 1 22 105 Sensitivity .820 .740  .880 
 0 45 23 Specificity .671 .545  .778 
IV 1 18 115 Sensitivity .766 .689  .831 
 0 34 35 Specificity .653 .508  .777 
 
 
I found that the estimated specificities based on the group memberships predicted 
by the four logistic regression models (see Table 22) were consistently higher than those 
estimated for the ECHOGRADE scores (see Table 18 and Table 19) but consistently 
lower than those estimated for the HVW scores (see Table 20 and Table 21). The 
midpoint specificities for the female patients using Models I and III (59.0% and 67.1%) 
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were relatively similar to the specificities for the male patients using Models II and IV 
(63.3% and 65.3%). Because the 95% confidence intervals were wide, and overlapped, 
no significant differences between the specificities at the .05 level with respect to the 
BMI of the patients could be inferred.  
Conclusions 
The findings are summarized with bar charts to facilitate visual interpretation of 
the data. 
Demographics 
The sample of 522 patients included an approximate 1:1 ratio of male patients to 
female patients. The dominant racial group was Hispanic, followed by White, Other 
races, and Black. Male patients and female patients were relatively equally represented 
within each racial group. Over half of the patients were classified as overweight to obese 
(BMI = 25-35 kg/m
2
), with more than one tenth of patients classified as excessively 
obese (BMI > 35 kg/m
2
). Liver disease was diagnosed as present in the majority (n = 326, 
62.5%) of patients. The point estimates of the prevalence of liver disease were relatively 
equally distributed between genders, and most prevalent among the Hispanic female 
patients. 
Testing of Null Hypothesis 
I analyzed morphometric and physiological data for 522 patients, constructed four 
binary logistic regression models, and estimated sensitivities and specificities to test the 
hypothesis that the pressure gradient in the portal vein, splenic vein, or hepatic vein; and 
increased liver echogenicity, hepatic venous waveform, or portal vein diameter are 
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associated with the diagnosis of liver disease after controlling for gender, ethnicity, and 
BMI. I obtained the following evidence to support the rejection of the null hypothesis:  
RACE. The ORs indicated that the likelihood of Hispanic female patients having 
liver disease was about 2 to 3 times greater than for female patients who were not 
Hispanic. The ORs for White and Black patients relative to other races were not 
significantly different from 1, indicating that the likelihoods of liver disease in Black and 
White patients were not greater than for the other races.  
 PVD. The mean PVD was highest in patients with liver disease. I observed 
significant differences between the mean PVD measurements of male patients and female 
patients in the presence and absence of liver disease. Sexual dimorphism of the portal 
vein had implications for the computation of the MPVPG in the absence of liver disease. 
 MPVPG. When liver disease was absent, the MPVPG in male patients was 
similar to that in female patients. When liver disease was present, the MPVPG was 
elevated, and significantly higher in male patients than in female patients . The responses 
of men and women to the measures of MPVPG are summarized in Figure 7. The ORs 
were consistently higher in male patients than in female patients, implying that an 
elevated MPVPG indicated a greater likelihood of liver disease in men than in women. 
Within each gender, the ORs with respect to MPVPG were similar when patients with a 
BMI > 35 were included, compared to the ORs when patients with a BMI > 35 were 
excluded.   
112 
 
 
Gender
BMI
MaleFemale
<35>35<35>35
3.0
2.5
2.0
1.5
1.0
O
d
d
s
 R
a
ti
o
 
Figure 7. Responses of male patients and female patients to measures of MPVPG. 
 
SVPG. I found a significant difference in the SVPG between genders. The 
responses of men and women to the measures of SVPG are summarized in Figure 8. The 
ORs were not significantly different from 1 in female patients, but significantly less than 
1 in male patients. This finding implied that when the SVPG was elevated, the likelihood 
of liver disease was less in men, but not so in women. Within each gender, the ORs for 
SVPG were similar in patients in the two groups stratified according to their BMI. 
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Figure 8. Responses of male and female patients to measures of SVPG. 
 
HVPG. The mean measures of the HVPG were not significantly different with 
respect to gender. The responses of men and women to the measures of HVPG are 
compared in Figure 9. The pattern of the ORs with respect to gender was similar to that 
observed for the SVPGs (see Figure 8); however, because the ORs in both male patients 
and female patients were not significantly different from 1, associated with the wide 95% 
CIs, there was no statistical evidence to indicate that the HVPG could be used as a 
predictor of liver disease. The ORs for HVPG did not differ with respect to BMI. 
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Figure 9. Responses of male and female patients to measures of HVPG. 
 
ECHOGRADE. The ORs for the sonographic measures of echogenicity were 
higher than those for the Doppler-derived pressure gradients; however, the ORs were not 
comparable, because the scales of measurement were different (logarithms for the 
pressure gradients and ordinal categories for ECHOGRADE). The differences between 
the responses of men and women are illustrated in Figure 10.    
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Figure 10. Responses of male and female patients to sonographic measures of 
echogenicity. 
 
A systematic stepwise increase in the OR with respect to a unit increase in 
ECHOGRADE was observed in female patients. In male patients, however, there was 
little change in the OR between ECHOGRADE 2 and 3. The ORs were consistently 
lower when female patients with a BMI > 35 were included compared to the ORs when 
female patients with a BMI > 35 were excluded. In contrast, the ORs were consistently 
higher in the male patients group, which included those with BMIs > 35.   
HVW. The differences between the responses of men and women to the HVW 
phases are summarized in Figure 11. The ORs were less than for ECHOGRADE. In male 
patients, there was a systematic reduction in the OR with respect to an increase in HVW 
from 1 (monophasic) to 2 (biphasic) relative to triphasic (normal). The biphasic 
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waveform was only a marginally significant predictor of liver disease in women with a 
BMI < 35. When women with a BMI > 35 were included in the analysis, the ORs for 
both the monophasic and biphasic waveforms were not significantly different from 1. 
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Figure 11. Responses to male patients and female patients to the HVW phases. 
 
ROC Curves 
The inferences that I drew from the ROC curves were that (a) the sensitivity for 
each given cutoff level of MPVPG was generally higher among male patients than among 
female patients; and (b) when any given level of MPVPG assumed to represent a positive 
test for liver disease was lowered, both the sensitivity and the false-positive rate tended to 
increase. The curves were not rectilinear, with a clear inflexion point, which could be 
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used as a criterion for choosing a level of MPVPG to represent positive test results. I 
tentatively suggest a possible cutoff to diagnose liver disease of about 50 mmHg mm
4
. 
Sensitivity and Specificity 
 For a visual comparison of the sensitivities of ECHOGRADE (1, 2, and 3 relative 
to 0), MPVPG ( ≥ 50 relative to < 50 mmHg mm4), and HVW (1 and 2 relative to 3) with 
respect to male patients and female patients (see Figure 12). 
Gender Test
Male
Female
HVW 1
HVW 2
MPVPG > 50
ECHOGRADE 3
ECHOGRADE 2
ECHOGRADE 1
HVW 1
HVW 2
MPVPG > 50
ECHOGRADE 3
ECHOGRADE 2
ECHOGRADE 1
1.00.80.60.40.20.0
Sensitivity
 
Figure 12. Comparison of sensitivities of ECHOGRADE, MPVPG, and HVW. 
 
The conditional probabilities that the tests will be positive if liver disease is 
present were consistently higher for the three levels of ECHOGRADE than for the 
MPVPG and the HVW. The sensitivity for MPVPG using a cutoff point of 50 mmHg 
mm
4
 was higher in male patients than in female patients. The sensitivities for both the 
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biphasic and monophasic waveforms were consistently higher in male patients than in 
female patients. Evidence is provided to indicate that the probabilities of true-positive 
responses to the three diagnostic tests for liver disease varied with respect to gender.  
For a comparison of the specificities of ECHOGRADE (1, 2, and 3 relative to 0) 
MPVPG ( ≥ 50 relative to < 50 mmHg mm4), and HVW (1 and 2 relative to 3) with 
respect to male patients and female patients (see Figure 13). 
Gender Test
Male
Female
HVW 1
HVW 2
MPVPG > 50
ECHOGRADE 3
ECHOGRADE 2
ECHOGRADE 1
HVW 1
HVW 2
MPVPG > 50
ECHOGRADE 3
ECHOGRADE 2
ECHOGRADE 1
0.90.80.70.60.50.40.30.20.10.0
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Figure 13. Comparison of specificities of ECHOGRADE, MPVPG, and HVW. 
 
The conditional probabilities that the tests will be negative if liver disease is 
absent were consistently lower for the three levels of ECHOGRADE than for the 
monophasic and triphasic measures of HVW. Both the ECHOGRADE scores and the 
HVW levels provided higher specificities than the MPVPG. The specificities for 
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ECHOGRADE were consistently lower in male patients than in female patients, whereas 
the specificities for HVW in male patients and female patients were similar. The 
specificity for the MPVPG using my suggested cutoff level of 50 mmHg mm
4
 was higher 
in male patients than in female patients. It is evident that the probabilities of true-negative 
responses to the three diagnostic tests for liver disease varied with respect to gender.
 I found no consistent improvements in sensitivity or specificity when the 
estimates were based on the predicted presence or absence of liver disease using the 
logistic regression models containing multiple variables including MPVPG, 
ECHOGRADE, and HVW. 
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Chapter 5: Discussion 
Overview 
 In this study, I tested the hypothesis that the Doppler-derived pressure gradient in 
the portal vein (MPVPG), splenic vein (SVPG), or hepatic vein (HVPG), and increased 
liver echogenicity (ECHOGRADE score), hepatic venous waveform (HVW level), or 
portal vein diameter (PVD) is associated with the diagnosis of liver disease after 
controlling for gender, ethnicity, and BMI. The statistical evidence that I obtained to 
reject the null hypothesis is discussed in this chapter. The rationale for my study was that 
chronic liver disease is a significant burden accounting for approximately $9 billion per 
year in health care expenditures. Currently, the gold standard for diagnosing liver disease 
is biopsy; however, liver biopsy is invasive and harbors significant risks to patients with 
chronic liver disease, including bleeding and infection. The purpose of this study was to 
determine the extent to which Doppler-derived pressure gradients of the portal, hepatic, 
and splenic vein, ECHOGRADE, and HVW could accurately detect liver disease, and 
thereby reduce the need for invasive biopsies. Sonographic imaging is one potential 
alternative (Nicolau et al., 2002); however, with the substantial increase in rates of 
obesity, the ability to determine fatty infiltration from fibrosis by imaging alone has 
become more difficult. Consequently, sonographic imaging may be less effective for the 
detection of  liver disease in patients who are excessively obese (defined a BMI > 35 
kg/m
2
). Obrador et al. (2006) proposed that Doppler-derived pressure gradients in 
addition to sonographic images may increase the sensitivity for the detection of chronic 
liver disease. Consequently, I evaluated Doppler-derived pressure gradients and HVWs 
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for their applicability as possible alternatives for the noninvasive diagnosis of liver 
disease. Abnormal changes in the hepatic circulation may potentially provide diagnostic 
tests with higher sensitivity and lower specificity for the detection of hepatocellular 
disease than sonographic measures of echogenicity.  
 I analyzed a preexisting data set based on a convenience sample of 522 patients 
treated at a medical center in the western United States from March 2010 to December 
2010. The data set was de-identified with no patient identifiers at the time of the analysis. 
The data analysis involved descriptive statistics, binary logistic regression, and estimates 
of sensitivity and specificity, including ROC curves, as follows. 
Descriptive Statistics 
Liver disease was prevalent among all races (White, Black, Hispanic, Asian, and 
North American Indian), with the highest prevalence among Hispanic female patients 
(46.5%). The PVD measurements (mm) for the 522 patients were normally distributed. 
When liver disease was absent, the mean PVD (mm) in male patients was not 
significantly different from that of female patients; however, when liver disease was 
present, indicated by enzyme levels, I observed sexual dimorphism of the portal vein. The 
mean PVD was significantly wider in male patients than in female patients.  
I found that the Doppler-derived pressure gradients were not normally distributed 
but could be normalized by logarithmic transformation. When liver disease was absent, 
the modified portal vein pressure gradient (MPVPG), computed as a function of the 
PVPG and the PVD, was similar in both male patients and female patients. When liver 
disease was present, the MPVPG was elevated and significantly higher in male patients 
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than in female patients. I also found significant differences between the SVGP but not the 
HVGP with respect to gender and the presence or absence of liver disease.  
Binary Logistic Regression 
I used binary logistic regression to construct four models to predict the likelihood 
of the dependent variable DISEASE, represented by 1 = liver disease is present 
(diagnosed by enzyme tests) and 0 = absent. The independent variables were MPVPG, 
HVPG, SVGP, ECHOGRADE, and HVW. I stratified the results by gender and BMI 
(including excessively obese patients with BMI > 35 or excluding patients with BMI > 
35). Even though there were only 57 subjects with a BMI > 35, I believed it was of value 
to determine if excessive obesity influenced the results. I controlled for RACE (White, 
Black, Hispanic, or Other) as a categorical covariate. 
Sensitivity and Specificity 
The ROC curves for male patients and female patients based on the MPVPG 
measures were not rectilinear with obvious inflexion points, which could be used as 
criteria for choosing a level of MPVPG to represent positive test results (Dawson & 
Trapp, 2004). When any given level of MPVPG assumed to represent a positive test for 
liver disease was lowered, then both the sensitivity and the false-positive rate tended to 
increase. I tentatively suggest a possible cutoff level to diagnose liver disease at an 
MPVPG of about 50 mmHg mm
4
.  
The specificities were consistently higher for the three levels of ECHOGRADE 
than for the MPVPG and the HVW. The sensitivity for MPVPG using my proposed 
cutoff point of 50 mmHg mm
4
 was higher in male patients than in female patients. The 
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sensitivities for both the biphasic and monophasic waveforms were consistently higher in 
male patients than in female patients. The specificities were consistently lower for the 
three levels of ECHOGRADE than for the monophasic and triphasic measures of HVW. 
Both the ECHOGRADE scores and the HVW levels provided higher specificities than 
the MPVPG. The specificities for ECHOGRADE were consistently lower in male 
patients than in female patients, whereas the specificities for HVW in male patients and 
female patients were similar.  
Limitations of Study 
 There were few limitations to the study. The sample size was not small, with a 
near-equal distribution of male patients (n = 251, 48.1%) and female patients (n = 271, 
51.9%). An a priori power analysis indicated that the sample sizes were above the 
minimum required to correctly reject the null hypothesis at α = .05 with a statistical 
power of .80 using binary logistic regression. A post-hoc power analysis indicated that 
the sample sizes of 271, 251, 229, and 236 used in the four binary logistic regression 
models provided powers of .992, .987, .979, and .982, respectively.  
This study was based on a convenience sample because the variables used in the 
statistical analysis were not collected at random, but extracted from a database at one 
medical center in the western United States. No attempt was made to ensure that the 
variables accurately and completely represented the population. Nevertheless, the sample 
population matched the overall mix of races represented by the geographic region, and 
the ratio of male patients to female patients was approximately equal. Because the sample 
of patients in this investigation was not necessarily representative of every patient with 
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liver disease in the United States, the results cannot necessarily be generalized so that 
they apply to that population. The convenience sample used in this investigation might 
represent a threat to the external validity of the results; nevertheless, medical researchers 
frequently employ convenience samples for practical reasons (Kuzma & Bohnenblust, 
2005).  
A potential limitation to the study was the generalization of several groups of 
diseases into one dependent variable of liver disease. Based on the different 
hepatocellular and physiological changes that develop different types of liver diseases 
(e.g., cirrhosis versus gallbladder disease), it is possible that the Doppler-derived pressure 
gradients might have yielded greater prognostic value if the dependent variable had been 
classified into multiple diseases. 
Interpretation of Findings 
RACE 
The odds ratios (ORs) indicated that the likelihood of Hispanic female patients 
having liver disease was about 2 to 3 times greater than female patients who were not 
Hispanic; however, the likelihood of liver disease in Black and White patients were not 
greater those in other races. The data collected in the Fourth National Health and 
Nutrition Examination Survey also indicated that the prevalence of risk factors for liver 
disease varied by race. According to that survey, Hispanics and Blacks have a greater risk 
of developing liver disease than their White counterparts (Flores et al., 2008).      
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PVD 
The increase that I observed in the diameter of the portal vein in patients with 
liver disease, including sexual dimorphism, reflects the potential clinical significance of 
this morphometric measure as an alternative diagnostic test. My results, however, have 
not been confirmed by other researchers. In comparison, Weinreb et al. (1982), working 
in the United States, reported that the mean PVD (mm) in 107 healthy adult patients, 
aged 21 to 40 years, based on sonographic measures (M = 11.0, SD = 2.0), was higher 
than in my study (with no difference between male patients and female patients). Solhjoo, 
Mansour-Ghanaei, and Moulaei-Langorudi (2011), working in Iran, similarly reported 
larger mean portal vein diameters (mm) than those reported in my study. They found no 
significant difference between 31 patients with nonalcoholic liver disease (M = 10.77, SD 
= 1.51 mm) and 31 controls (M = 10.35, SD = 1.57 mm). The differences between the 
results of my study and others could be due to sampling bias and/or due to the use of 
different instrumentation to estimate the PVD.  
HVW 
 I found that the hepatic vein waveform proved to be a useful noninvasive measure 
to predict the presence of liver disease. The HVW was a marginally significant predictor 
of liver disease in women with a BMI < 35. If HVW = 2, then the likelihood of liver 
disease was about 2.5 times greater than if HVW = 3 (normal). HVW was also a 
significant predictor of liver disease in male patients, including those with BMI > 35. If 
HVW = 1 (i.e., monophasic), then the likelihood of a male patient having liver disease 
was about 6.5 times greater than a patient whose HVW = 3 (i.e., triphasic). If HVW = 2 
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(i.e., biphasic), then the likelihood of a man having liver disease would be, on average, 
approximately 2.5 times greater than if the HVW was triphasic. The reason for this 
outcome was that increased intrahepatic blood pressure  may generate abnormal 
continuous monophasic or biphasic waveforms in the hepatic vein. In healthy patients, 
the HVW is usually triphasic because of the movement of the tricuspid valve annulus 
toward the heart apex, atrial overfilling, tricuspid valve opening, and the atrial 
contraction (Goldberg & McGahan, 2006). When the liver hardens due to disease, the 
hepatic veins can become compressed and show a more continuous flow pattern. The 
results of my study validated the observations of Goldberg and McGahan (2006) and 
Solhjoo et al. (2011) by identifying a statistically significant relationship between the 
HVW and liver disease.  
ECHOGENICITY 
I found that measures of echogenicity generally provided the highest ORs to 
predict the presence of liver disease, rather than the hepatic vein waveform or the 
pressure gradients. ECHOGENICITY also provided consistently higher sensitivities and 
lower specificities.Elevated measures of echogenicity appeared to indicate a greater 
likelihood of liver disease in women than in men, and there was evidence that a high BMI 
influenced these measures. The data support my suggestion that sonographic imaging 
may be less effective to detect liver disease if the sample includes excessively obese 
patients.  
My results are consistent with those reported by Obrador et al. (2006), who found 
that obesity may causes architectural and hence echogenic changes in the liver in the 
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absence of underlying liver disease. Rumack et al.(2005) also concluded that a fat-
infiltrated liver with increased size and echogenicity confounds the diagnosis of liver 
fibrosis. Although obesity was presumed to hinder the ability of sonography to 
distinguish fatty infiltration from liver fibrosis leading to cirrhosis, the results of my 
study indicated that ECHOGRADE remains a more consistent indicator of liver disease 
than does the HVW.  
Pressure Gradients 
The data I collected to describe the variability in the MPVG appear to reflect the 
potential clinical significance of Doppler-derived hemodynamic measures as an 
alternative diagnostic test for liver disease. A comprehensive and exhaustive search of 
journals and electronic databases yielded no published studies against which to compare 
the results of my analysis of the portal vein pressure gradients, taking into account the 
variability of the portal vein diameter, in order to predict the presence of liver disease. 
My results confirmed other observations that acute or chronic liver disease may block the 
blood flow throughout the liver, causing blood to back up into the hepatic portal 
circulation, resulting in portal vein hypertension and expansion (Hagen-Ansert, 2006).   
The ORs for the MPVPG were less than those for ECHOGRADE; however, the 
ORs were not directly comparable because of the different scales of measurement used. 
The ORs measured between the successive ordinal increments of ECHOGRADE, from 1 
to 2 to 3, relative to ECHOGRADE 0, corresponded to substantial differences in liver 
disease status (i.e., 1 = grainy liver (vessels and diaphragm seen); 2 = fatty liver (vessels 
not seen, diaphragm seen); and 3 = fatty liver (vessels and diaphragm not seen) relative to 
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0 = normal (not echogenic). In contrast, the ORs measured between successive 
logarithmic increments in MPVPG measured in mmHg mm
4
, did not indicate comparable 
differences in liver disease status to those indicated by the ordinal categories of 
ECHOGRADE. For example, the likelihood of liver disease would be about twice as high 
in a patient with a logt MVPG of 2 (equivalent to a measured MPVG of 100 mmHg mm
4
) 
than in a patient with a logt MPVPG of 1 (equivalent to a measured MPVPG of 10 
mmHg mm
4
). The likelihood of liver disease would be about twice as high in a patient 
with a logt MVPG of 3 (equivalent to a measured MPVG of 1000 mmHg mm
4
) than in a 
patient with a logt MPVPG of 2 (equivalent to a measured MPVPG of 10 mmHg mm
4
).   
The main problem limiting the use of the MPVPG to detect liver disease is its 
relatively low sensitivity and relatively high specificity compared to measures of 
echogenicity. I found that the ROC curve had a shallow slope and did not include an 
obvious inflexion that could be used to accurately predict the presence of liver disease. 
Gender differences also confounded the results.The specificity for the MPVPG using my 
suggested cut-off level of 50 mmHg mm
4
 was higher in male patients than in female 
patients. I found no consistent improvements in sensitivity or specificity when the 
estimates were based on the predicted presence or absence of liver disease using the 
logistic regression models containing multiple variables, including MPVPG, 
ECHOGRADE, and HVW. 
My results were consistent with those reported by Bernatik et al. (2002), who 
noted that where severe fibrosis and cirrhosis were identified, there were hemodynamic 
changes in the hepatic vein (biphasic or monophasic). The addition of Doppler-derived 
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pressure gradients was not, however, of clinical significance in assessing the stage of 
liver fibrosis or for differentiating mild fibrosis from severe fibrosis. In conclusion, I was 
not able to confirm my suggestion that abnormal changes in the hepatic circulation may 
provide tests with higher sensitivity and lower specificity for the diagnosis of 
hepatocellular disease than sonographic measures of echogenicity.    
Implications for Social Change 
Chronic liver disease, whether caused by hepatitis, alcoholism, or NALFD, is a 
major health problem that results in increased morbidity and greater expenditures of 
health care dollars (CDC, 2005). Alcoholic hepatitis is the third leading preventable cause 
of death in the United States (Lucey et al., 2009), and it is estimated that as many as 70 
million Americans may be diagnosed with NALFD (Angulo, 2002). The health care 
burden of chronic liver disease is substantial (Bugianesi, 2005). This burden includes a 
financial strain on the health care system, as well as a long, debilitating illness for the 
individual patients. The American Gastroenterological Association (as cited in Kim et al., 
2002) estimated the economic burden of common gastrointestinal and liver disorders, 
including chronic liver disease, chronic HepC, liver cancer, and gallbladder disease as 
accounting for approximately one quarter ($9.1 billion) of all direct costs for health care.  
The results of this study have confirmed that alternative, noninvasive methods 
(echogenicity, hepatic waveform, and possibly the MPVPG) have clinical significance to 
detect liver disease. This noninvasive approach can aid referring physicians to more 
effectively treat patients whose acute liver disease is starting to progress into chronic 
liver disease. With earlier aggressive treatment and intervention, severe adverse health 
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outcomes leading to irreversible liver cirrhosis might be avoided. Prevention of liver 
disease is not always possible, but early intervention and treatment might lead to a 
decrease in morbidity and mortality related to chronic liver disease. The results of this 
study may lead to social change that could possibly improve the human condition of 
individuals living with liver disease. There is evidence that alternative testing such as the 
use of fibroelastosis and biochemical markers are helping to predict liver fibrosis 
(Pickerell, 2010; Ratziu et al., 2006). This study adds to the current body of knowledge 
and yielded worthwhile insight into the value of providing alternative, noninvasive 
methods to predict liver disease and encourage less reliance on liver biopsy alone.   
Recommendations for Action 
 The results of this study showed that an ECHOGRADE of 2 or 3 predicts liver 
disease in both men and women. An HVW of 1 predicts liver disease in men and an 
HVW of 2 may predict liver disease in women. Not all imaging facilities grade liver 
echogenicity, instead recording only ―fatty infiltration of the liver.‖ Based on the results 
of this study, I recommend both grading of ECHOGRADE and adding HVWs to the 
abdominal sonographic protocols to help in the early detection of liver disease. This study 
included two novel applications. First, applying cardiac presets (from the Bernoulli 
equation) allowed velocity measurements in the hepatic, portal, and splenic veins to be 
displayed in pressure gradients. Hepatologists who are accustomed to working with 
pressure gradients rather than velocity measurements should consider using this 
alternative measurement if sonographic software is available. Second, the portal vein 
diameter increases with liver disease. The modified pressure gradient (taking into account 
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this increase in diameter) did not prove statistically significant in female patients but did 
in male patients when using all types of liver disease as the dependent variable. 
Recommendations regarding the modified pressure gradient warrant a separate 
discussion, which follows in the next section.   
Recommendations for Further Study 
 The results of this study indicate that ECHOGRADE and HVW are statistically 
significant predictors of liver disease, and Doppler-derived pressure gradients may also 
have the potential to predict liver disease, but are not as sensitive as ECHOGRADE and 
HVW. Based on these results, I recommend that future researchers not conduct further 
investigations on the HVPG or SVPG. Instead, I recommend future researchers to 
determine if the MPVPG will predict different types of liver disease status. Due to the 
large number of independent variables in the present study, as well as the restricted 
sample size, it was unfeasible to break down the dependent variable into separate groups. 
My clinical justification for predicting the variable STATUS (see Table 23) using 
MPVPG as an independent variable is that my preliminary analysis (not included in 
chapter 4) indicated that the mean logt MPVPG measurements increased systematically 
with respect to a change in liver disease status (see Figure 14). 
  
132 
 
 
Table 23 
 
Suggested Independent Variable 
Variable Definition Level Groups 
STATUS Presence of a 
specified type of liver 
disease 
Nominal 0 = liver disease is absent 
1 = gallbladder (GB) disease 
2 = hepatitis 
3 = NASH and NAFLD 
4 = cirrhosis and ascites  
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Figure 14. Relationship between liver disease status and mean logt MPVPGs ± 95% CIs. 
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 I recommend future researchers utilize STATUS to make the research more 
meaningful, because the independent variables could predict not only disease or no 
disease, but also the specific type of disease. In a multinominal logistic regression model, 
the dependent variable represents three or more numerically coded qualitative categories 
(e.g., 0 = liver disease is absent; 1 = gallbladder (GB) disease; 2 = hepatitis; 3 = NASH 
and NAFLD; 4 = cirrhosis and ascites) but no implicit hierarchy or order is implied by 
the codes. Since the maximum likelihood or optimization algorithm might be limited 
when more than one independent variable is included (Hosmer & Lemeshow, 2000), I 
decided to forego using STATUS as a dependent variable in this study. However, now 
that the analysis has been performed using several other independent variables that 
proved to be of limited statistical significance, STATUS might be reintroduced in future 
studies. Such a model could use the independent variables that populate a statistically 
significant correlation in predicting liver disease (ECHOGRADE, HVW, and MPVPG 
only) using the binary logistic regression model to predict each disease status. Future 
researchers might want to consider conducting additional studies with laboratory liver 
panels (i.e., MELD scores) with ECHOGRADE and HVW to try and increase the 
diagnostic accuracy of multiple noninvasive tests. MRE shows promise as a noninvasive 
measure and should be monitored for advancements in this technology to noninvasively 
predict liver disease.  
Studies similar to this study need to be conducted to evaluate regional differences 
in predicting liver disease using these sonographic measures. In this study, I applied the 
Bernoulli equation to change velocity to pressure gradients. This application was a novel 
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approach to abdominal sonography and should be tested in other regional facilities to 
determine the utility and efficacy for referring physicians. Application of the MPVPG 
and HVW in all abdominal sonograms will help to validate this method and provide an 
additional method of screening for liver disease across the nation and abroad.  
Dissemination of Results 
Key stakeholders in the study included hepatologists, internal medicine 
physicians, radiologists, sonographers, sonography professional organizations, and 
epidemiologists. Findings resulting from the study will be disseminated through 
presentations at scholarly sonography and hepatology conventions commonly attended by 
medical and/or epidemiology professionals. Results of the study will be provided to those 
physicians who routinely refer patient to the participating hospital for abdominal 
sonographic examinations.  
Conclusions 
The results from this study showed significant associations between 
ECHOGRADE, HVW, and liver disease using this noninvasive sonographic 
methodology. This study will add to the current body of knowledge in sonographic 
methodology to help predict disease before irreversible liver damage occurs. In both male 
patients and female patients, as the ECHOGRADE of the liver increased, so did the risk 
of liver disease. The HVW had an inverse relationship with liver disease. As the HVW 
decreased from triphasic to monophasic, the OR increased for liver disease. In this study, 
Doppler-derived pressure gradients of the hepatic, portal, and splenic vein were not so 
sensitive measure of liver disease. Future researchers should consider separating the 
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dependent variable into multiple liver disease states. The-Doppler-derived pressure 
gradients used in this study might predict certain types of liver disease but may be 
nonspecific when all types of liver disease are combined.  
This study introduced two novel methods. One method involved applying the 
cardiac presets to the abdominal sonogram to change velocity measurements to pressure 
gradients. This method might help referring hepatologists who work with pressure 
gradients rather than velocity measurements in their clinical practice to correlate clinical 
findings with the recorded venous pressure gradients. A new mathematical modifier was 
used, which took into account the known dilatation of the portal vein with increasing 
liver fibrosis and multiplied it by the portal vein pressure gradient. This mathematical 
modifier might provide a pathway for additional research following the hemodynamic 
principles laid down by pioneers in vascular pathophysiology where the largest 
contributing factor in flow is a reduction or increase in radius.  
The literature review conducted for this study demonstrated that liver disease 
remains a major health care burden, both in terms of human suffering and fiscal impact. 
The current gold standard in detecting liver disease is liver biopsies, but these tests are 
invasive and harbor significant risks. Results of this study offer a positive social change 
in the form of an alternate noninvasive sonographic method to predict liver disease. Use 
of this method could result in earlier clinical interventions before irreversible liver 
damage occurs as well as reduce the number of invasive liver biopsies, which could lead 
to improvements in overall health status and reductions in overall health costs. 
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Appendix A: Instrumentation Used in Creating the Data Set 
Ultrasound 
 The ultrasound equipment used in performing the sonograms was a high-
resolution general imaging ultrasound system. The ultrasound transducers used for 
obtaining the measurements in the data set included both the 4-MHz vector array 
transducer and 6-MHz curved array transducer, depending on the patient body habitus. 
Both of these transducers had vascular applications to perform both color and spectral 
Doppler examinations. Six ultrasound units of like kind were used to obtain the required 
data. Each machine had yearly preventive maintenance checks and the machines were 
calibrated to the manufacturer specifications. All machines had the same software 
platforms to ensure as little variability as possible between machines.    
Sonographic Protocol 
 For all participants, I consistently followed the sonographic protocol used in 
creating the data set. All participants received a complete abdominal sonographic 
examination using the standard imaging protocol followed at the health care center. All 
sonographic procedures adhered to the ―as low as reasonably achievable‖ principle of 
exposure. Although no adverse bioeffects have been confirmed as attributable to the use 
of ultrasound for diagnostic purposes, following the principle of minimizing exposure 
ensured that the exam was done only when medically indicated and in a timely fashion. 
Following is the abdominal sonogram protocol I used to collect the data that was 
analyzed as part of the study.  
1. I introduced myself (the sonographer) to the patient. 
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2. I explained the examination to the patient. 
3. I obtained a complete patient history related to the current visit. This history 
included reviewing any relevant laboratory or ancillary imaging reports.  
4. I placed the patient in a supine position and placed towels below the patient’s 
shirt and above the pants to protect the patient’s clothing from the acoustic 
gel. 
5. I applied warm gel to the patient’s abdomen. 
6. I chose an appropriate transducer, based on the patient’s body habitus, with 
which to conduct the examination. I used a 4-MHz vector array (4V2) 
transducer on large patients or to obtain images between the ribs. A 6-MHz 
curved linear array (6C3) was optimum if the images could be obtained 
subcostally and the frequency of the transducer could penetrate the region of 
interest.  
7. I obtained longitudinal and transverse images of the following organs: liver, 
pancreas, gallbladder, kidneys, and spleen. I obtained additional oblique 
images of the gallbladder in the left lateral decubitus position. I also took 
longitudinal and transverse measurements of each organ, as well as 
measurements of the common bile duct, and gallbladder wall, and the 
anterior-posterior measurement of the portal vein. 
8. I took color and spectral Doppler measurements of the following vessels: right 
portal vein, middle and right hepatic vein, and splenic vein. I took all of the 
Doppler measurements with an imaging angle of between 0 and 20 degrees to 
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ensure an accurate Doppler measurement. The color region of interest box was 
narrowed to improve the temporal resolution and increase the frame rate 
(fewer color lines over time). The sample volume (gate) was set at 1-2 mm to 
only detect flow in the center of the vessel. The pulse repetition frequency 
(scale) was set such that the waveform would take up approximately 50% of 
the Doppler scale. To obtain a pressure gradient from a velocity measurement, 
I changed the imaging presets to a cardiac setting. This routine step was 
adopted for all abdominal sonograms and was not specific to the participants 
in this study. This change involved me taking the following steps on the 
ultrasound machine: 
a. going to setup; 
b. selecting the Settings/Measurements/Calipers option; 
c. on the dropdown list, switching protocol from Abdominal to Cardiac 
Doppler presets; and 
d. returning to the main menu to continue imaging. 
9. I had the patient reposition to a position in which both the middle and right 
hepatic vein could be imaged at a 0- to 20-degree angle. 
10. I obtained the color Doppler signal. Under normal conditions, the hepatic 
veins traveling away from the transducer are displayed in blue. The color 
Doppler signal is useful (and I used it) to confirm the presence of flow as well 
as the direction of flow in the intrahepatic vessels.  
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11. I obtained the spectral Doppler component, placed the sample volume (gate) 
within the hepatic vein and then recorded the waveform.  
12. I froze the image on the display screen and measured the peak systolic 
velocity of the respective hepatic vein.  
13. I placed the second caliper over the velocity measurement to obtain the 
pressure gradient. 
14. I recorded the pressure gradient of both the middle and right hepatic veins on 
the worksheet. Using the same technique and Doppler angle, I obtained the 
venous waveform in the right portal vein and splenic vein.  
15. I took additional images if pathology was detected.  
16. I wiped off the patient’s abdomen and escorted the patient out of the room. 
17. I filled out the technical worksheet and scanned it into the system for review 
by the radiologist. 
18. I sent the final report to the referring physician.  
Sonographic Data 
 I graded the liver texture in the sonographic analysis and recorded the grade in the 
data set. A grade of 0 reflected normal texture. A grade of 1 equated to a mildly coarse 
texture and increased echogenicity; the diaphragm and intrahepatic vessels were well 
visualized. A grade of 2 referred to a moderately diffuse coarseness of the liver texture 
and increased echogenicity; the diaphragm and intrahepatic vessels were difficult to 
visualize. A grade of 3 reflected a marked diffuse coarseness of the liver texture with or 
without liver lobulation; the diaphragm and intrahepatic vessels were poorly or not 
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visualized. In addition to grading the liver texture, I noted the liver contour as either 
smooth or lobulated.  
 With cirrhosis, liver echogenicity decreases and the liver itself becomes nodular 
and shrinks in size (Hagen-Ansert, 2006). I noted the presence or absence of 
splenomegaly and ascites. I obtained the diameter of the right portal vein at a 90-degree 
angle (normal incidence) to the vessel wall. I obtained an anterior-posterior dimension 
from the inner wall to inner wall of the vessel lumen. As reported by Hagen-Ansert 
(2006), an anterior-posterior dimension of greater than 1.3 cm has been found in patients 
with cirrhosis and portal hypertension.  
 Hepatic venous waveform analysis. The hepatic venous waveform in a healthy 
liver is triphasic. This waveform is a reflection of the tricuspid annulus moving toward 
the apex, the tricuspid valve opening, and the atrial contraction of the heart. With 
increased intrahepatic pressure due to obstruction such as that caused by fibrosis or 
cirrhosis, or congestion such as that caused by tricuspid valve regurgitation, the triphasic 
waveform can be lost. The pattern will first become biphasic with loss of the atrial 
contraction wave and eventually become monophasic with a constant antegrade signal 
due to venous obstruction (Goldberg & McGahan, 2006). I graded the hepatic venous 
signal at the time of the abdominal sonogram in the following manner: 3 = triphasic, 2 = 
biphasic, 1 = monophasic.  
 Hepatic, portal, and splenic venous pressure gradient. The hepatic venous 
pressure in a healthy liver is less than 5mmHg, as measured by the technique described in 
Sonographic Protocol. The right portal venous signal should reflect a continuous pattern 
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and flow toward the transducer. Pulsation in the flow is suggestive of right heart failure 
such as severe tricuspid regurgitation (Zwiebel & Pellerito, 2005). The splenic vein 
should display flow away from the transducer in a continuous pattern. I imaged the 
splenic hilum (i.e., where the vessels connect with the spleen) to identify the presence of 
splenic varices in the setting of an enlarged spleen and cirrhotic liver. Splenic varices are 
dilated veins that enlarge in the setting of portal hypertension (Hagen-Ansert, 2006). I 
noted the presence of varices, as well as both color and spectral Doppler within the 
varices. I recorded the recorded pressure gradient of the portal vein, splenic vein, and 
right hepatic vein in the data set for further statistical analysis. I also recorded the 
presence or absence of varices in the data set.    
Determination of Disease Status  
 I used patient referral for an abdominal sonogram and self-reported health 
symptoms as well as the respective patient medical records to determine the disease 
status. Disease status included history of alcohol abuse, NAFLD, HepC, or other known 
liver diseases such as hepatocellular carcinoma. I checked laboratory values to determine 
a history of hepatocellular disease, including ALT and AST. If the patient had increased 
ALT levels, the laboratory results also included a second-generation enzyme-linked 
immunosorbent assay antibody to HepC (anti-HCV) to determine the presence or absence 
of HepC. I checked liver biopsy results at the time of the abdominal sonogram to 
determine those patients with liver fibrosis or cirrhosis. I checked endoscopy results to 
determine the presence or absence of esophageal varices. 
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Appendix B: Sample of Data Set 
Gender
a 
Disease
b 
Disease 
status
c 
PV diam.
d 
PVPG
e 
HVPG
f 
HVW
g 
SVPG
h 
EG
i 
Ht
j 
Wt
k 
ALT
l 
AST
m 
Ethnicity
n
 
1 0 0 0.5 0.1 0.2 2 0.1 1 67 134 0 0 4 
2 0 0 0.7 0.2 0.3 2 
x 
remove 2 65 185 1 1 4 
1 1 3 1.8 0.3 0.2 1 0.2 3 69 190 1 1 1 
2 1 1 0.9 0.1 0.2 3 0.1 3 60 159 0 0 4 
2 1 1 1 0.2 0.5 3 0.1 2 62 180 1 1 4 
1 0 0 0.6 0.1 0.3 3 0.6 3 64 195 0 0 1 
2 0 0 0.5 0.1 0.3 3 0.1 2 67 170 0 0 2 
1 1 2 0.8 0.1 0.7 3 0.2 3 65 155 1 1 3 
1 0 0 0.8 0.1 0.4 3 0.1 2 63 175 1 1 4 
2 1 3 0.8 0.2 0.8 1 0.1 2 64 162 1 1 4 
1 0 0 0.65 0.1 0.7 3 0.1 3 63 150 0 0 4 
1 0 0 0.7 0.1 0.4 2 0.1 3 64 185 1 1 4 
1 0 0 0.7 0.2 0.5 3 0.1 3 56 205 1 1 3 
1 1 1 0.7 0.1 0.2 2 0.2 3 64 185 1 1 3 
1 1 4 1.5 0.1 0.3 1 
 
2 
  
1 1 4 
 
Note. 
a
Gender: 1 = male, 2 = female. 
b
Disease: 1 = yes, 2 = no. 
c
Disease status: 0 = no, 1 = GB disease, 2 = hepatitis, 3 = NASH, 
fatty liver, 4 = cirrhosis/ascites. 
d
 PV diam. = portal vein diameter. 
e
PVPG = Portal vein pressure gradient measured in mmHg. 
f
HVPG = hepatic vein pressure gradient measured in mmHg. 
g
HVW = hepatic vein waveform, 1 = monophasic, 2 = biphasic, 3 = 
triphasic. 
h
SVPG = splenic vein pressure gradient measured in mmHg.
 i
0 = normal, 1 = coarse, 2 = echogenic liver, vessels seen, 
nonvisualized diaphragm, 3 = echogenic, nonvisualized vessels or diaphragm.
 j
Ht = height in inches. 
k
Wt = weight in pounds. 
l
ALT = elevated ALT liver function test: 1 = yes, 2 = no. 
m
AST = elevated AST liver function test: 1 = yes, 2 = no. 
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